{"_meta":{"title":"Vaccine pipeline progress schema and adoption outlook model","built":"2026-10-24","version":"20261024","inputs":{"candidates":"vaccine_pipeline_data.json (candidate records, lastUpdated 2026-07-10)","trials":"vaccine_pipeline_ctgov_raw.json (ClinicalTrials.gov v2, fetched 2026-07-10, 1,856 vaccine trials)"},"how_to_read":"Progress is a position on a fixed ladder, not a probability of success. Projected windows are scenario bands built from the parameters listed here; the slow band is not an upper bound. Bands are only produced for jurisdictions with a verified review target."},"candidates":[{"candidateId":"mrna-1010","name":"mRNA-1010","developer":"Moderna","targetDisease":"Seasonal influenza","platform":"mRNA","stage":"regulatory_submission_filed","stage_label":"Submitted to a regulator","stage_at_discontinuation":null,"progress_percent":75,"grade":"B","grade_reason":"Dates are the company's own estimates.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/mrna-1010.html","expectedMilestone":"Regulatory decision(s) pending across filed jurisdictions (company projection)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"regulatory_submission_filed","status_date":"2026-01","date_type":"company_estimate","windows":{"fast":{"submission":"2026-01","decision":"2026-11","routine_use":"2026-11"},"typical":{"submission":"2026-01","decision":"2026-11","routine_use":"2027-02"},"slow":{"submission":"2026-01","decision":"2027-04","routine_use":"2027-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"regulatory_submission_filed","status_date":"2026-01","date_type":"company_estimate","windows":{"fast":{"submission":"2026-01","decision":"2026-10","routine_use":"2026-11"},"typical":{"submission":"2026-01","decision":"2027-03","routine_use":"2027-09"},"slow":{"submission":"2026-01","decision":"2027-09","routine_use":"2029-03"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"regulatory_submission_filed","status_date":"2026-01","date_type":"company_estimate","windows":{"fast":{"submission":"2026-01","decision":"2026-11","routine_use":"2026-12"},"typical":{"submission":"2026-01","decision":"2026-11","routine_use":"2027-03"},"slow":{"submission":"2026-01","decision":"2027-04","routine_use":"2028-04"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"regulatory_submission_filed","status_date":"2026-01","date_type":"company_estimate","note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"mrna-1083","name":"mRNA-1083 (Moderna Combined Influenza + COVID-19 mRNA Vaccine)","developer":"Moderna","targetDisease":"Seasonal influenza + COVID-19 (combination)","platform":"mRNA","stage":"regulatory_submission_filed","stage_label":"Submitted to a regulator","stage_at_discontinuation":null,"progress_percent":75,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-08-01","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/mrna-1083.html","expectedMilestone":"FDA target PDUFA action date and ACIP review for 2025-2026 respiratory season","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"under_review","status_date":"2024-10-15","date_type":"regulator_confirmed","windows":{"fast":{"submission":"2024-10","decision":"2026-11","routine_use":"2026-11"},"typical":{"submission":"2024-10","decision":"2027-01","routine_use":"2027-04"},"slow":{"submission":"2024-10","decision":"2027-07","routine_use":"2028-03"}},"anchor":"2025-20","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"under_review","status_date":"2024-11-01","date_type":"company_estimate","windows":{"fast":{"submission":"2024-11","decision":"2026-11","routine_use":"2026-12"},"typical":{"submission":"2024-11","decision":"2027-01","routine_use":"2027-07"},"slow":{"submission":"2024-11","decision":"2027-07","routine_use":"2029-01"}},"anchor":"2025-20","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"not_filed","status_date":"2025-02-01","date_type":"company_estimate","windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2025-20","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"not_filed","status_date":"2025-03-01","date_type":"company_estimate","note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"vax-31-adult","name":"VAX-31 (adult)","developer":"Vaxcyte","targetDisease":"Invasive pneumococcal disease (31-valent conjugate)","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"B","grade_reason":"Dates are the company's own estimates.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/vax-31-adult.html","expectedMilestone":"Topline data from OPUS-1 (company: Q4 2026); planned BLA submission to follow if positive","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"phase_3","status_date":"2026","date_type":"company_estimate","windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"vla15","name":"VLA15","developer":"Valneva / Pfizer","targetDisease":"Lyme disease","platform":"Protein subunit (OspA)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"B","grade_reason":"Dates are the company's own estimates.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/vla15.html","expectedMilestone":"VALOR Phase 3 field efficacy results (company: H1 2026); BLA/MAA planned if positive","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"phase_3","status_date":"H1 2026 field efficacy readout (company)","date_type":"company_estimate","windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"phase_3","status_date":"H1 2026 field efficacy readout (company)","date_type":"company_estimate","windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ixchiq","name":"Ixchiq (VLA1553 / Chikungunya live-attenuated vaccine)","developer":"Valneva","targetDisease":"Chikungunya","platform":"Live attenuated","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-08-01","relatedVaccinePage":null,"page":"/pipeline/ixchiq.html","expectedMilestone":"Post-marketing safety surveillance; adolescent trial data readout","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2023-11-09","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2023-11","routine_use":null},"typical":{"submission":null,"decision":"2023-11","routine_use":null},"slow":{"submission":null,"decision":"2023-11","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"approved","status_date":"2024-06-28","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-06","routine_use":null},"typical":{"submission":null,"decision":"2024-06","routine_use":null},"slow":{"submission":null,"decision":"2024-06","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"approved","status_date":"2024-06-14","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-06","routine_use":null},"typical":{"submission":null,"decision":"2024-06","routine_use":null},"slow":{"submission":null,"decision":"2024-06","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"under_review","status_date":"2024-09-01","date_type":"company_estimate","note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"mrna-1345-rsv","name":"mRNA-1345 (mRESVIA context / next-gen RSV programs)","developer":"Moderna","targetDisease":"RSV","platform":"mRNA","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/mrna-1345-rsv.html","expectedMilestone":"Label expansions / seasonal updates as disclosed; see licensed RSV page for post-licensure safety","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2024+","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-12","routine_use":null},"typical":{"submission":null,"decision":"2024-12","routine_use":null},"slow":{"submission":null,"decision":"2024-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"pfizer-dual-flu-covid","name":"Influenza + COVID combination candidates (Pfizer/BioNTech family)","developer":"Pfizer / BioNTech","targetDisease":"Seasonal influenza + COVID-19 (combination)","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/pfizer-dual-flu-covid.html","expectedMilestone":"Phase 3 readouts and potential regulatory filings (company-dependent; verify latest 10-Q/investor materials)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"phase_3","status_date":"verify current phase on ClinicalTrials.gov","date_type":"unknown","windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"novavax-flu-covid","name":"COVID-Influenza Combination (CIC) — Novavax","developer":"Novavax","targetDisease":"Seasonal influenza + COVID-19 (combination)","platform":"Protein nanoparticle + Matrix-M","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"B","grade_reason":"Dates are the company's own estimates.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/novavax-flu-covid.html","expectedMilestone":"Phase 3 data and potential regulatory path (company projection — verify latest filings)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"phase_3","status_date":"verify on ClinicalTrials.gov / company pipeline","date_type":"company_estimate","windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-abrysvo","name":"ABRYSVO","developer":"Pfizer Inc.","targetDisease":"RSV","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/fda-abrysvo.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2023-05-31","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2023-05","routine_use":null},"typical":{"submission":null,"decision":"2023-05","routine_use":null},"slow":{"submission":null,"decision":"2023-05","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-arexvy","name":"AREXVY","developer":"GlaxoSmithKline Biologicals","targetDisease":"RSV","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/fda-arexvy.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2023-05-03","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2023-05","routine_use":null},"typical":{"submission":null,"decision":"2023-05","routine_use":null},"slow":{"submission":null,"decision":"2023-05","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-capvaxive","name":"CAPVAXIVE","developer":"See FDA listing","targetDisease":"Pneumococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/fda-capvaxive.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2024","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-12","routine_use":null},"typical":{"submission":null,"decision":"2024-12","routine_use":null},"slow":{"submission":null,"decision":"2024-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-comirnaty","name":"COMIRNATY","developer":"Pfizer-BioNTech","targetDisease":"COVID-19","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/fda-comirnaty.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2021-08-23","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2021-08","routine_use":null},"typical":{"submission":null,"decision":"2021-08","routine_use":null},"slow":{"submission":null,"decision":"2021-08","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-covid-19-vaccine-adjuvanted","name":"COVID-19 Vaccine, Adjuvanted","developer":"See FDA listing","targetDisease":"COVID-19","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/fda-covid-19-vaccine-adjuvanted.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-covid-19-vaccine-mrna","name":"COVID-19 Vaccine, mRNA","developer":"See FDA listing","targetDisease":"COVID-19","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/fda-covid-19-vaccine-mrna.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-cyfendus","name":"CYFENDUS","developer":"Emergent BioSolutions","targetDisease":"Anthrax","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/fda-cyfendus.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2023-07-20","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2023-07","routine_use":null},"typical":{"submission":null,"decision":"2023-07","routine_use":null},"slow":{"submission":null,"decision":"2023-07","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-chikungunya-vaccine-recombinant","name":"Chikungunya Vaccine, Recombinant","developer":"See FDA listing","targetDisease":"Chikungunya","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/fda-chikungunya-vaccine-recombinant.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-dengue-tetravalent-vaccine-live","name":"Dengue Tetravalent Vaccine, Live","developer":"See FDA listing","targetDisease":"Dengue","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/fda-dengue-tetravalent-vaccine-live.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-a","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Mening","developer":"See FDA listing","targetDisease":"Meningococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/fda-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-a.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-ebola-zaire-vaccine-live","name":"Ebola Zaire Vaccine, Live","developer":"See FDA listing","targetDisease":"Ebola","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/fda-ebola-zaire-vaccine-live.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-hepatitis-b-vaccine-recombinant","name":"Hepatitis B Vaccine (Recombinant)","developer":"See FDA listing","targetDisease":"Hepatitis B","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-b-vaccine.html","page":"/pipeline/fda-hepatitis-b-vaccine-recombinant.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-hepatitis-b-vaccine-recombinant-adjuvanted","name":"Hepatitis B Vaccine (Recombinant), Adjuvanted","developer":"See FDA listing","targetDisease":"Hepatitis B","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-b-vaccine.html","page":"/pipeline/fda-hepatitis-b-vaccine-recombinant-adjuvanted.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-human-papillomavirus-9-valent-vaccine-recombinant","name":"Human Papillomavirus 9-valent Vaccine, Recombinant","developer":"See FDA listing","targetDisease":"HPV","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/fda-human-papillomavirus-9-valent-vaccine-recombinant.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-ixchiq","name":"Ixchiq (VLA1553 / Chikungunya live-attenuated vaccine)","developer":"Valneva Austria GmbH","targetDisease":"Chikungunya","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-08-01","relatedVaccinePage":null,"page":"/pipeline/fda-ixchiq.html","expectedMilestone":"Post-marketing safety surveillance; adolescent trial data readout","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2023-11-09","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2023-11","routine_use":null},"typical":{"submission":null,"decision":"2023-11","routine_use":null},"slow":{"submission":null,"decision":"2023-11","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"approved","status_date":"2024-06-28","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-06","routine_use":null},"typical":{"submission":null,"decision":"2024-06","routine_use":null},"slow":{"submission":null,"decision":"2024-06","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"approved","status_date":"2024-06-14","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-06","routine_use":null},"typical":{"submission":null,"decision":"2024-06","routine_use":null},"slow":{"submission":null,"decision":"2024-06","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"under_review","status_date":"2024-09-01","date_type":"company_estimate","note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-influenza-a-h5n1-monovalent-vaccine-adjuvanted","name":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","developer":"See FDA listing","targetDisease":"Influenza","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/fda-influenza-a-h5n1-monovalent-vaccine-adjuvanted.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-influenza-vaccine","name":"Influenza Vaccine","developer":"See FDA listing","targetDisease":"Influenza","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/fda-influenza-vaccine.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-influenza-vaccine-quadrivalent","name":"Influenza Vaccine (Quadrivalent)","developer":"See FDA listing","targetDisease":"Influenza","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/fda-influenza-vaccine-quadrivalent.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-influenza-vaccine-trivalent","name":"Influenza Vaccine (Trivalent)","developer":"See FDA listing","targetDisease":"Influenza","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/fda-influenza-vaccine-trivalent.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-influenza-vaccine-adjuvanted","name":"Influenza Vaccine, Adjuvanted","developer":"See FDA listing","targetDisease":"Influenza","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/fda-influenza-vaccine-adjuvanted.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-influenza-virus-vaccine-trivalent-types-a-and-b","name":"Influenza Virus Vaccine(Trivalent, Types A and B)","developer":"See FDA listing","targetDisease":"Influenza","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/fda-influenza-virus-vaccine-trivalent-types-a-and-b.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-mnexspike","name":"MNEXSPIKE","developer":"See FDA listing","targetDisease":"COVID-19","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/fda-mnexspike.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2025","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2025-12","routine_use":null},"typical":{"submission":null,"decision":"2025-12","routine_use":null},"slow":{"submission":null,"decision":"2025-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-measles-mumps-and-rubella-vaccine-live","name":"Measles, Mumps and Rubella Vaccine, Live","developer":"See FDA listing","targetDisease":"Measles / Mumps / Rubella","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"mmr-vaccine.html","page":"/pipeline/fda-measles-mumps-and-rubella-vaccine-live.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-meningococcal-group-b-vaccine","name":"Meningococcal Group B Vaccine","developer":"See FDA listing","targetDisease":"Meningococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/fda-meningococcal-group-b-vaccine.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-meningococcal-groups-a-b-c-w-and-y-vaccine","name":"Meningococcal Groups A, B, C, W, and Y Vaccine","developer":"See FDA listing","targetDisease":"Meningococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/fda-meningococcal-groups-a-b-c-w-and-y-vaccine.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-nuvaxovid","name":"NUVAXOVID","developer":"Novavax, Inc.","targetDisease":"COVID-19","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/fda-nuvaxovid.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2025","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2025-12","routine_use":null},"typical":{"submission":null,"decision":"2025-12","routine_use":null},"slow":{"submission":null,"decision":"2025-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-penbraya","name":"PENBRAYA","developer":"See FDA listing","targetDisease":"Meningococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/fda-penbraya.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2023","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2023-12","routine_use":null},"typical":{"submission":null,"decision":"2023-12","routine_use":null},"slow":{"submission":null,"decision":"2023-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-penmenvy","name":"PENMENVY","developer":"See FDA listing","targetDisease":"Meningococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/fda-penmenvy.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2025","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2025-12","routine_use":null},"typical":{"submission":null,"decision":"2025-12","routine_use":null},"slow":{"submission":null,"decision":"2025-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-priorix","name":"PRIORIX","developer":"GlaxoSmithKline Biologicals","targetDisease":"Measles / Mumps / Rubella","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"mmr-vaccine.html","page":"/pipeline/fda-priorix.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2022-06-03","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2022-06","routine_use":null},"typical":{"submission":null,"decision":"2022-06","routine_use":null},"slow":{"submission":null,"decision":"2022-06","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-pneumococcal-15-valent-conjugate-vaccine","name":"Pneumococcal 15-valent Conjugate Vaccine","developer":"See FDA listing","targetDisease":"Pneumococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/fda-pneumococcal-15-valent-conjugate-vaccine.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-pneumococcal-20-valent-conjugate-vaccine","name":"Pneumococcal 20-valent Conjugate Vaccine","developer":"See FDA listing","targetDisease":"Pneumococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/fda-pneumococcal-20-valent-conjugate-vaccine.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-pneumococcal-21-valent-conjugate-vaccine","name":"Pneumococcal 21-valent Conjugate Vaccine","developer":"See FDA listing","targetDisease":"Pneumococcal disease","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/fda-pneumococcal-21-valent-conjugate-vaccine.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-respiratory-syncytial-virus-vaccine","name":"Respiratory Syncytial Virus Vaccine","developer":"See FDA listing","targetDisease":"RSV","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/fda-respiratory-syncytial-virus-vaccine.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-respiratory-syncytial-virus-vaccine-adjuvanted","name":"Respiratory Syncytial Virus Vaccine, Adjuvanted","developer":"See FDA listing","targetDisease":"RSV","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/fda-respiratory-syncytial-virus-vaccine-adjuvanted.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-spikevax","name":"SPIKEVAX","developer":"ModernaTX, Inc.","targetDisease":"COVID-19","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/fda-spikevax.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2022-01-31","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2022-01","routine_use":null},"typical":{"submission":null,"decision":"2022-01","routine_use":null},"slow":{"submission":null,"decision":"2022-01","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-smallpox-and-monkeypox-vaccine-live-non-replicating","name":"Smallpox and Monkeypox Vaccine, Live, Non-Replicating","developer":"See FDA listing","targetDisease":"Mpox / Smallpox","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/fda-smallpox-and-monkeypox-vaccine-live-non-replicating.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-vaxelis","name":"VAXELIS","developer":"MCM Vaccine Company","targetDisease":"Diphtheria / Tetanus / Pertussis / Polio / Hib / HepB","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"dtap-vaccine.html","page":"/pipeline/fda-vaxelis.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2018-12-21","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2018-12","routine_use":null},"typical":{"submission":null,"decision":"2018-12","routine_use":null},"slow":{"submission":null,"decision":"2018-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-vimkunya","name":"VIMKUNYA","developer":"See FDA listing","targetDisease":"Chikungunya","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/fda-vimkunya.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2025","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2025-12","routine_use":null},"typical":{"submission":null,"decision":"2025-12","routine_use":null},"slow":{"submission":null,"decision":"2025-12","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-zoster-vaccine-recombinant-adjuvanted","name":"Zoster Vaccine Recombinant, Adjuvanted","developer":"See FDA listing","targetDisease":"Varicella / Zoster","platform":"Licensed biologic (see FDA product page)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/fda-zoster-vaccine-recombinant-adjuvanted.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"see FDA page","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2026-10","routine_use":"2026-10"},"typical":{"submission":null,"decision":"2026-10","routine_use":"2027-01"},"slow":{"submission":null,"decision":"2026-10","routine_use":"2027-06"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"fda-mresvia","name":"mRESVIA","developer":"ModernaTX, Inc.","targetDisease":"RSV","platform":"See FDA product page / label","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/fda-mresvia.html","expectedMilestone":"US-licensed — see product label / ACIP for use; further supplements may expand indication","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2024-05-31","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-05","routine_use":null},"typical":{"submission":null,"decision":"2024-05","routine_use":null},"slow":{"submission":null,"decision":"2024-05","routine_use":null}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2026-10","decision":"2027-12","routine_use":"2028-06"},"slow":{"submission":"2026-10","decision":"2028-06","routine_use":"2029-12"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2026-10","decision":"2027-04","routine_use":"2027-05"},"typical":{"submission":"2026-10","decision":"2027-08","routine_use":"2027-12"},"slow":{"submission":"2026-10","decision":"2028-01","routine_use":"2029-01"}},"anchor":"2026-10","anchor_type":"today (no dated milestone)"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mcv4-cansino-biologics-inc","name":"MCV4","developer":"CanSino Biologics Inc.","targetDisease":"Epidemic Meningitis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-mcv4-cansino-biologics-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2025-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2024-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2024-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2024-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1273-variant-containing-formulation-modernatx-inc","name":"mRNA-1273 Variant-containing Formulation","developer":"ModernaTX, Inc.","targetDisease":"COVID-19","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-mrna-1273-variant-containing-formulation-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-vaxigrip-tetra-sanofi-pasteur-europe-aarhus-university-hospital","name":"Vaxigrip Tetra Sanofi Pasteur Europe","developer":"Aarhus University Hospital","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-vaxigrip-tetra-sanofi-pasteur-europe-aarhus-university-hospital.html","expectedMilestone":"Primary completion (most advanced trial): 2026-05-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-recombinant-zoster-vaccine-glaxosmithkline","name":"Recombinant zoster vaccine","developer":"GlaxoSmithKline","targetDisease":"Varicella / Zoster","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-recombinant-zoster-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2030-04-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-01","routine_use":"2031-01"},"typical":{"submission":"2031-01","decision":"2031-11","routine_use":"2032-02"},"slow":{"submission":"2031-10","decision":"2033-01","routine_use":"2033-09"}},"anchor":"2030-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-04","routine_use":"2031-05"},"typical":{"submission":"2031-01","decision":"2032-03","routine_use":"2032-09"},"slow":{"submission":"2031-10","decision":"2033-06","routine_use":"2034-12"}},"anchor":"2030-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-01","routine_use":"2031-02"},"typical":{"submission":"2031-01","decision":"2031-11","routine_use":"2032-03"},"slow":{"submission":"2031-10","decision":"2033-01","routine_use":"2034-01"}},"anchor":"2030-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-sipv-sinovac-biotech-co-ltd","name":"sIPV","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Polio","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"polio-vaccine.html","page":"/pipeline/ctgov-sipv-sinovac-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-04-11 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-moderna-covid-19-vaccine-well-konnect-healthcare-services-and-re","name":"Moderna COVID-19 Vaccine","developer":"Well- Konnect Healthcare Services and Research Firm","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-moderna-covid-19-vaccine-well-konnect-healthcare-services-and-re.html","expectedMilestone":"Primary completion (most advanced trial): 2030-09-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-12","decision":"2031-06","routine_use":"2031-06"},"typical":{"submission":"2031-06","decision":"2032-04","routine_use":"2032-07"},"slow":{"submission":"2032-03","decision":"2033-06","routine_use":"2034-02"}},"anchor":"2030-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-12","decision":"2031-09","routine_use":"2031-10"},"typical":{"submission":"2031-06","decision":"2032-08","routine_use":"2033-02"},"slow":{"submission":"2032-03","decision":"2033-11","routine_use":"2035-05"}},"anchor":"2030-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-12","decision":"2031-06","routine_use":"2031-07"},"typical":{"submission":"2031-06","decision":"2032-04","routine_use":"2032-08"},"slow":{"submission":"2032-03","decision":"2033-06","routine_use":"2034-06"}},"anchor":"2030-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-2wipv-1sipv-sinovac-biotech-co-ltd","name":"3wIPV","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Polio","platform":"Inactivated","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"polio-vaccine.html","page":"/pipeline/ctgov-2wipv-1sipv-sinovac-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-09-08 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-vaicella-vaccine-dtap-on-day-0-mmr-on-day-30-sinovac-dalian-vacc","name":"Varicella Vaccine","developer":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","targetDisease":"Measles / Mumps / Rubella","platform":"Live attenuated","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"mmr-vaccine.html","page":"/pipeline/ctgov-vaicella-vaccine-dtap-on-day-0-mmr-on-day-30-sinovac-dalian-vacc.html","expectedMilestone":"Primary completion (most advanced trial): 2025-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rsv-vaccination-arexvy-glaxosmithkline-chinese-university-of-hon","name":"RSV vaccination (Arexvy, GlaxoSmithKline)","developer":"Chinese University of Hong Kong","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsv-vaccination-arexvy-glaxosmithkline-chinese-university-of-hon.html","expectedMilestone":"Primary completion (most advanced trial): 2030-06-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-09","decision":"2031-03","routine_use":"2031-03"},"typical":{"submission":"2031-03","decision":"2032-01","routine_use":"2032-04"},"slow":{"submission":"2031-12","decision":"2033-03","routine_use":"2033-11"}},"anchor":"2030-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-09","decision":"2031-06","routine_use":"2031-07"},"typical":{"submission":"2031-03","decision":"2032-05","routine_use":"2032-11"},"slow":{"submission":"2031-12","decision":"2033-08","routine_use":"2035-02"}},"anchor":"2030-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-09","decision":"2031-03","routine_use":"2031-04"},"typical":{"submission":"2031-03","decision":"2032-01","routine_use":"2032-05"},"slow":{"submission":"2031-12","decision":"2033-03","routine_use":"2034-03"}},"anchor":"2030-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-prophylactic-quadrivalent-hpv-vaccine-merck-gardasil-partha-basu","name":"Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)","developer":"Partha Basu","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-prophylactic-quadrivalent-hpv-vaccine-merck-gardasil-partha-basu.html","expectedMilestone":"Primary completion (most advanced trial): 2017-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2017-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2017-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2017-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1273-moderna-covid-19-vaccine-tor-biering-s-rensen","name":"mRNA-1273 (Moderna COVID-19 vaccine)","developer":"Tor Biering-Sørensen","targetDisease":"COVID-19","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-mrna-1273-moderna-covid-19-vaccine-tor-biering-s-rensen.html","expectedMilestone":"Primary completion (most advanced trial): 2026-08 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-healive-hepatitis-a-vacine-human-diploid-cell-inactivated-sinova","name":"Healive (hepatitis A vacine(human diploid cell), inactivated)","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Hepatitis A","platform":"Inactivated","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-a-vaccine.html","page":"/pipeline/ctgov-healive-hepatitis-a-vacine-human-diploid-cell-inactivated-sinova.html","expectedMilestone":"Primary completion (most advanced trial): 2028-03-17 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-06","decision":"2028-12","routine_use":"2028-12"},"typical":{"submission":"2028-12","decision":"2029-10","routine_use":"2030-01"},"slow":{"submission":"2029-09","decision":"2030-12","routine_use":"2031-08"}},"anchor":"2028-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-06","decision":"2029-03","routine_use":"2029-04"},"typical":{"submission":"2028-12","decision":"2030-02","routine_use":"2030-08"},"slow":{"submission":"2029-09","decision":"2031-05","routine_use":"2032-11"}},"anchor":"2028-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-06","decision":"2028-12","routine_use":"2029-01"},"typical":{"submission":"2028-12","decision":"2029-10","routine_use":"2030-02"},"slow":{"submission":"2029-09","decision":"2030-12","routine_use":"2031-12"}},"anchor":"2028-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-moderna-rsv-vaccine-emory-university","name":"Moderna RSV vaccine","developer":"Emory University","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-moderna-rsv-vaccine-emory-university.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rmenb-omv-nz-glaxosmithkline","name":"rMenB+OMV NZ","developer":"GlaxoSmithKline","targetDisease":"Meningococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-rmenb-omv-nz-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-09-07 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1273-modernatx-inc","name":"mRNA-1273","developer":"ModernaTX, Inc.","targetDisease":"COVID-19","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-mrna-1273-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-06-16 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-09","decision":"2028-03","routine_use":"2028-03"},"typical":{"submission":"2028-03","decision":"2029-01","routine_use":"2029-04"},"slow":{"submission":"2028-12","decision":"2030-03","routine_use":"2030-11"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-09","decision":"2028-06","routine_use":"2028-07"},"typical":{"submission":"2028-03","decision":"2029-05","routine_use":"2029-11"},"slow":{"submission":"2028-12","decision":"2030-08","routine_use":"2032-02"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-09","decision":"2028-03","routine_use":"2028-04"},"typical":{"submission":"2028-03","decision":"2029-01","routine_use":"2029-05"},"slow":{"submission":"2028-12","decision":"2030-03","routine_use":"2031-03"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-nvx-cov2705-novavax","name":"NVX-CoV2705","developer":"Novavax","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-nvx-cov2705-novavax.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-18 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-08","routine_use":"2027-08"},"typical":{"submission":"2027-08","decision":"2028-06","routine_use":"2028-09"},"slow":{"submission":"2028-05","decision":"2029-08","routine_use":"2030-04"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-11","routine_use":"2027-12"},"typical":{"submission":"2027-08","decision":"2028-10","routine_use":"2029-04"},"slow":{"submission":"2028-05","decision":"2030-01","routine_use":"2031-07"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-08","routine_use":"2027-09"},"typical":{"submission":"2027-08","decision":"2028-06","routine_use":"2028-10"},"slow":{"submission":"2028-05","decision":"2029-08","routine_use":"2030-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-live-attenuated-varicella-vaccine-sinovac-dalian-vaccine-technol","name":"Live Attenuated Varicella Vaccine","developer":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","targetDisease":"Varicella / Zoster","platform":"Live attenuated","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-live-attenuated-varicella-vaccine-sinovac-dalian-vaccine-technol.html","expectedMilestone":"Primary completion (most advanced trial): 2028-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-09"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-10"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-05"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2029-09","decision":"2030-11","routine_use":"2031-05"},"slow":{"submission":"2030-06","decision":"2032-02","routine_use":"2033-08"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-10"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-11"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-09"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-investigational-live-attenuated-varicella-vaccine-sinovac-dalian","name":"Placebo (Freeze Dired Dilution)","developer":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","targetDisease":"Varicella / Zoster","platform":"Live attenuated","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-investigational-live-attenuated-varicella-vaccine-sinovac-dalian.html","expectedMilestone":"Primary completion (most advanced trial): 2021-12-19 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2021-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2021-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2021-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-cervarix-glaxosmithkline","name":"Havrix","developer":"GlaxoSmithKline","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-cervarix-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2012-01-16 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-azd1222-astrazeneca","name":"AZD1222","developer":"AstraZeneca","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-azd1222-astrazeneca.html","expectedMilestone":"Primary completion (most advanced trial): 2023-04-19 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-mrna-covid-19-vaccine-novartis-pharmaceuticals","name":"mRNA COVID-19 vaccine","developer":"Novartis Pharmaceuticals","targetDisease":"COVID-19","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-mrna-covid-19-vaccine-novartis-pharmaceuticals.html","expectedMilestone":"Primary completion (most advanced trial): 2023-04-14 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-dtp-hb-hib-vaccine-serum-institute-of-india-pvt-ltd","name":"DTP-HB-Hib vaccine","developer":"Serum Institute of India Pvt. Ltd.","targetDisease":"Hib","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hib-vaccine.html","page":"/pipeline/ctgov-dtp-hb-hib-vaccine-serum-institute-of-india-pvt-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2016-02 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-pneumo-23-wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","name":"Pneumo 23","developer":"Wyeth is now a wholly owned subsidiary of Pfizer","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pneumo-23-wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer.html","expectedMilestone":"See linked ClinicalTrials.gov records for primary completion dates","jurisdictions":{}},{"candidateId":"ctgov-rabipur-glaxosmithkline","name":"Rabipur","developer":"GlaxoSmithKline","targetDisease":"Rabies","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rabies-vaccine.html","page":"/pipeline/ctgov-rabipur-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2019-05-12 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-havrix-glaxosmithkline","name":"Havrix®","developer":"GlaxoSmithKline","targetDisease":"Hepatitis A","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-a-vaccine.html","page":"/pipeline/ctgov-havrix-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2019-01-28 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-experimental-vaccine-1-sinovac-research-and-development-co-ltd","name":"Experimental vaccine 1","developer":"Sinovac Research and Development Co., Ltd.","targetDisease":"COVID-19","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-experimental-vaccine-1-sinovac-research-and-development-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2023-03-20 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-bcg-denmark-1331-statens-serum-institute-bandim-health-project","name":"BCG-Denmark 1331 (Statens Serum Institute)","developer":"Bandim Health Project","targetDisease":"Tuberculosis","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"approved","progress_percent":90,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-bcg-denmark-1331-statens-serum-institute-bandim-health-project.html","expectedMilestone":"Primary completion (most advanced trial): 2021-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-9vhpv-vaccine-merck-sharp-dohme-llc","name":"9vHPV vaccine","developer":"Merck Sharp & Dohme LLC","targetDisease":"Papillomavirus Infections","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-9vhpv-vaccine-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2029-08-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-11","decision":"2028-05","routine_use":"2028-05"},"typical":{"submission":"2028-05","decision":"2029-03","routine_use":"2029-06"},"slow":{"submission":"2029-02","decision":"2030-05","routine_use":"2031-01"}},"anchor":"2027-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-11","decision":"2028-08","routine_use":"2028-09"},"typical":{"submission":"2028-05","decision":"2029-07","routine_use":"2030-01"},"slow":{"submission":"2029-02","decision":"2030-10","routine_use":"2032-04"}},"anchor":"2027-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-11","decision":"2028-05","routine_use":"2028-06"},"typical":{"submission":"2028-05","decision":"2029-03","routine_use":"2029-07"},"slow":{"submission":"2029-02","decision":"2030-05","routine_use":"2031-05"}},"anchor":"2027-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pcv21-vaccine-sanofi","name":"Rotarix","developer":"Sanofi","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pcv21-vaccine-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2027-09-10 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-09","decision":"2028-03","routine_use":"2028-03"},"typical":{"submission":"2028-03","decision":"2029-01","routine_use":"2029-04"},"slow":{"submission":"2028-12","decision":"2030-03","routine_use":"2030-11"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-09","decision":"2028-06","routine_use":"2028-07"},"typical":{"submission":"2028-03","decision":"2029-05","routine_use":"2029-11"},"slow":{"submission":"2028-12","decision":"2030-08","routine_use":"2032-02"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-09","decision":"2028-03","routine_use":"2028-04"},"typical":{"submission":"2028-03","decision":"2029-01","routine_use":"2029-05"},"slow":{"submission":"2028-12","decision":"2030-03","routine_use":"2031-03"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rsvpref-pfizer","name":"RSVpreF","developer":"Pfizer","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsvpref-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2027-01-18 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pg4-pfizer","name":"PG4","developer":"Pfizer","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pg4-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2027-12-02 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-08","decision":"2028-02","routine_use":"2028-02"},"typical":{"submission":"2028-02","decision":"2028-12","routine_use":"2029-03"},"slow":{"submission":"2028-11","decision":"2030-02","routine_use":"2030-10"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-08","decision":"2028-05","routine_use":"2028-06"},"typical":{"submission":"2028-02","decision":"2029-04","routine_use":"2029-10"},"slow":{"submission":"2028-11","decision":"2030-07","routine_use":"2032-01"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-08","decision":"2028-02","routine_use":"2028-03"},"typical":{"submission":"2028-02","decision":"2028-12","routine_use":"2029-04"},"slow":{"submission":"2028-11","decision":"2030-02","routine_use":"2031-02"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-experimental-vaccine-sinovac-biotech-co-ltd","name":"experimental vaccine","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Meningococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-experimental-vaccine-sinovac-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-08","routine_use":"2027-08"},"typical":{"submission":"2027-08","decision":"2028-06","routine_use":"2028-09"},"slow":{"submission":"2028-05","decision":"2029-08","routine_use":"2030-04"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-11","routine_use":"2027-12"},"typical":{"submission":"2027-08","decision":"2028-10","routine_use":"2029-04"},"slow":{"submission":"2028-05","decision":"2030-01","routine_use":"2031-07"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-08","routine_use":"2027-09"},"typical":{"submission":"2027-08","decision":"2028-06","routine_use":"2028-10"},"slow":{"submission":"2028-05","decision":"2029-08","routine_use":"2030-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-diphtheria-tetanus-and-acellular-pertussis-three-components-comb","name":"Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP","developer":"CanSino Biologics Inc.","targetDisease":"Diphtheria / Tetanus / Pertussis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"dtap-vaccine.html","page":"/pipeline/ctgov-diphtheria-tetanus-and-acellular-pertussis-three-components-comb.html","expectedMilestone":"Primary completion (most advanced trial): 2025-04-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2024-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2024-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2024-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-31-valent-pneumococcal-conjugate-vaccine-vaxcyte-inc","name":"PCV20","developer":"Vaxcyte, Inc.","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-31-valent-pneumococcal-conjugate-vaccine-vaxcyte-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2027-10","routine_use":"2027-10"},"typical":{"submission":"2027-10","decision":"2028-08","routine_use":"2028-11"},"slow":{"submission":"2028-07","decision":"2029-10","routine_use":"2030-06"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2028-01","routine_use":"2028-02"},"typical":{"submission":"2027-10","decision":"2028-12","routine_use":"2029-06"},"slow":{"submission":"2028-07","decision":"2030-03","routine_use":"2031-09"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-10","decision":"2028-08","routine_use":"2028-12"},"slow":{"submission":"2028-07","decision":"2029-10","routine_use":"2030-10"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-vla1553-valneva-austria-gmbh","name":"Ixchiq (VLA1553 / Chikungunya live-attenuated vaccine)","developer":"Valneva Austria GmbH","targetDisease":"Chikungunya","platform":"Biological (unspecified platform)","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-08-01","relatedVaccinePage":null,"page":"/pipeline/ctgov-vla1553-valneva-austria-gmbh.html","expectedMilestone":"Post-marketing safety surveillance; adolescent trial data readout","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2023-11-09","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2023-11","routine_use":null},"typical":{"submission":null,"decision":"2023-11","routine_use":null},"slow":{"submission":null,"decision":"2023-11","routine_use":null}},"anchor":"2023-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"approved","status_date":"2024-06-28","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-06","routine_use":null},"typical":{"submission":null,"decision":"2024-06","routine_use":null},"slow":{"submission":null,"decision":"2024-06","routine_use":null}},"anchor":"2023-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"approved","status_date":"2024-06-14","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-06","routine_use":null},"typical":{"submission":null,"decision":"2024-06","routine_use":null},"slow":{"submission":null,"decision":"2024-06","routine_use":null}},"anchor":"2023-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"under_review","status_date":"2024-09-01","date_type":"company_estimate","note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1647-modernatx-inc","name":"mRNA-1647","developer":"ModernaTX, Inc.","targetDisease":"CMV","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrna-1647-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2025-11-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rsvpref3-oa-vaccine-glaxosmithkline","name":"Placebo","developer":"GlaxoSmithKline","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsvpref3-oa-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-09-25 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-investigational-varicella-vaccine-glaxosmithkline","name":"Marketed varicella vaccine","developer":"GlaxoSmithKline","targetDisease":"Varicella / Zoster","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-investigational-varicella-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-23 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-08","routine_use":"2027-08"},"typical":{"submission":"2027-08","decision":"2028-06","routine_use":"2028-09"},"slow":{"submission":"2028-05","decision":"2029-08","routine_use":"2030-04"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-11","routine_use":"2027-12"},"typical":{"submission":"2027-08","decision":"2028-10","routine_use":"2029-04"},"slow":{"submission":"2028-05","decision":"2030-01","routine_use":"2031-07"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-02","decision":"2027-08","routine_use":"2027-09"},"typical":{"submission":"2027-08","decision":"2028-06","routine_use":"2028-10"},"slow":{"submission":"2028-05","decision":"2029-08","routine_use":"2030-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-sinovac-pcv13-sinovac-life-sciences-co-ltd","name":"Prevnar®","developer":"Sinovac Life Sciences Co., Ltd.","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-sinovac-pcv13-sinovac-life-sciences-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-05-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rabies-vaccine-serum-free-vero-cell-freeze-dried-sinovac-biotech","name":"Verorab®","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Rabies","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rabies-vaccine.html","page":"/pipeline/ctgov-rabies-vaccine-serum-free-vero-cell-freeze-dried-sinovac-biotech.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-tetanus-reduced-diphtheria-and-acellular-pertussis-five-componen","name":"23-valent Pneumococcal Polysaccharide Vaccine (PPV23)","developer":"CanSino Biologics Inc.","targetDisease":"Diphtheria / Tetanus / Pertussis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"dtap-vaccine.html","page":"/pipeline/ctgov-tetanus-reduced-diphtheria-and-acellular-pertussis-five-componen.html","expectedMilestone":"Primary completion (most advanced trial): 2025-05-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2024-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2024-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2024-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1345-modernatx-inc","name":"mRESVIA (mRNA-1345 / RSV vaccine)","developer":"ModernaTX, Inc.","targetDisease":"RSV","platform":"mRNA","stage":"approved","stage_label":"Approved / authorised","stage_at_discontinuation":null,"progress_percent":90,"grade":"A","grade_reason":"Regulator-confirmed status date in at least one jurisdiction.","lastVerified":"2026-08-01","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-mrna-1345-modernatx-inc.html","expectedMilestone":"Global commercial distribution; expanded adult age-group trials","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"approved","status_date":"2024-05-31","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-05","routine_use":null},"typical":{"submission":null,"decision":"2024-05","routine_use":null},"slow":{"submission":null,"decision":"2024-05","routine_use":null}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"approved","status_date":"2024-08-22","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-08","routine_use":null},"typical":{"submission":null,"decision":"2024-08","routine_use":null},"slow":{"submission":null,"decision":"2024-08","routine_use":null}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"approved","status_date":"2024-09-18","date_type":"regulator_confirmed","windows":{"fast":{"submission":null,"decision":"2024-09","routine_use":null},"typical":{"submission":null,"decision":"2024-09","routine_use":null},"slow":{"submission":null,"decision":"2024-09","routine_use":null}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"approved","status_date":"2024-11-05","date_type":"regulator_confirmed","note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bivalent-bnt162b2-original-omicron-ba-4-ba-5-3-microgram-dose-bi","name":"Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose","developer":"BioNTech SE","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-bivalent-bnt162b2-original-omicron-ba-4-ba-5-3-microgram-dose-bi.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07-23 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-tdv-takeda","name":"TDV","developer":"Takeda","targetDisease":"Dengue","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-tdv-takeda.html","expectedMilestone":"Primary completion (most advanced trial): 2027-04-14 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-07","decision":"2028-01","routine_use":"2028-01"},"typical":{"submission":"2028-01","decision":"2028-11","routine_use":"2029-02"},"slow":{"submission":"2028-10","decision":"2030-01","routine_use":"2030-09"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-07","decision":"2028-04","routine_use":"2028-05"},"typical":{"submission":"2028-01","decision":"2029-03","routine_use":"2029-09"},"slow":{"submission":"2028-10","decision":"2030-06","routine_use":"2031-12"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-07","decision":"2028-01","routine_use":"2028-02"},"typical":{"submission":"2028-01","decision":"2028-11","routine_use":"2029-03"},"slow":{"submission":"2028-10","decision":"2030-01","routine_use":"2031-01"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1403-modernatx-inc","name":"mRNA-1403","developer":"ModernaTX, Inc.","targetDisease":"Norovirus","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrna-1403-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-02-15 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-investigational-varicella-vaccine-lot-1-glaxosmithkline","name":"Marketed varicella vaccine_Lot 1","developer":"GlaxoSmithKline","targetDisease":"Varicella / Zoster","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-investigational-varicella-vaccine-lot-1-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-25 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mmrvns-glaxosmithkline","name":"MMRV","developer":"GlaxoSmithKline","targetDisease":"Measles / Mumps / Rubella","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"mmr-vaccine.html","page":"/pipeline/ctgov-mmrvns-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2028-02-28 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-05","decision":"2028-11","routine_use":"2028-11"},"typical":{"submission":"2028-11","decision":"2029-09","routine_use":"2029-12"},"slow":{"submission":"2029-08","decision":"2030-11","routine_use":"2031-07"}},"anchor":"2028-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-05","decision":"2029-02","routine_use":"2029-03"},"typical":{"submission":"2028-11","decision":"2030-01","routine_use":"2030-07"},"slow":{"submission":"2029-08","decision":"2031-04","routine_use":"2032-10"}},"anchor":"2028-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-05","decision":"2028-11","routine_use":"2028-12"},"typical":{"submission":"2028-11","decision":"2029-09","routine_use":"2030-01"},"slow":{"submission":"2029-08","decision":"2030-11","routine_use":"2031-11"}},"anchor":"2028-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-h5n1-vaccine-arepanrix-gsk-university-health-network-toronto","name":"H5N1 vaccine (Arepanrix, GSK)","developer":"University Health Network, Toronto","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-h5n1-vaccine-arepanrix-gsk-university-health-network-toronto.html","expectedMilestone":"Primary completion (most advanced trial): 2026-06-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-yellow-fever-vaccine-live-sanofi","name":"Yellow fever vaccine (live)","developer":"Sanofi","targetDisease":"Yellow fever","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"yellow-fever-vaccine.html","page":"/pipeline/ctgov-yellow-fever-vaccine-live-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2026-08-08 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1018-h5-modernatx-inc","name":"mRNA-1018-H5","developer":"ModernaTX, Inc.","targetDisease":"Influenza","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-mrna-1018-h5-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-01-28 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2027-10","routine_use":"2027-10"},"typical":{"submission":"2027-10","decision":"2028-08","routine_use":"2028-11"},"slow":{"submission":"2028-07","decision":"2029-10","routine_use":"2030-06"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2028-01","routine_use":"2028-02"},"typical":{"submission":"2027-10","decision":"2028-12","routine_use":"2029-06"},"slow":{"submission":"2028-07","decision":"2030-03","routine_use":"2031-09"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-10","decision":"2028-08","routine_use":"2028-12"},"slow":{"submission":"2028-07","decision":"2029-10","routine_use":"2030-10"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pcv13i-cansino-biologics-inc","name":"PCV13i","developer":"CanSino Biologics Inc.","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pcv13i-cansino-biologics-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-02-15 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-05","decision":"2027-11","routine_use":"2027-11"},"typical":{"submission":"2027-11","decision":"2028-09","routine_use":"2028-12"},"slow":{"submission":"2028-08","decision":"2029-11","routine_use":"2030-07"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-05","decision":"2028-02","routine_use":"2028-03"},"typical":{"submission":"2027-11","decision":"2029-01","routine_use":"2029-07"},"slow":{"submission":"2028-08","decision":"2030-04","routine_use":"2031-10"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-05","decision":"2027-11","routine_use":"2027-12"},"typical":{"submission":"2027-11","decision":"2028-09","routine_use":"2029-01"},"slow":{"submission":"2028-08","decision":"2029-11","routine_use":"2030-11"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-participants-will-receive-one-dose-of-vaccine-0-5-ml-of-sinovac-","name":"Vaxigrip QIV","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Influenza","platform":"Inactivated","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-participants-will-receive-one-dose-of-vaccine-0-5-ml-of-sinovac-.html","expectedMilestone":"Primary completion (most advanced trial): 2026-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pcv21-sanofi","name":"PCV21","developer":"Sanofi","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pcv21-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2027-01-07 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2027-10","routine_use":"2027-10"},"typical":{"submission":"2027-10","decision":"2028-08","routine_use":"2028-11"},"slow":{"submission":"2028-07","decision":"2029-10","routine_use":"2030-06"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2028-01","routine_use":"2028-02"},"typical":{"submission":"2027-10","decision":"2028-12","routine_use":"2029-06"},"slow":{"submission":"2028-07","decision":"2030-03","routine_use":"2031-09"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-04","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-10","decision":"2028-08","routine_use":"2028-12"},"slow":{"submission":"2028-07","decision":"2029-10","routine_use":"2030-10"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-provarix-sinovac-dalian-vaccine-technology-co-ltd","name":"PROVARIX","developer":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","targetDisease":"Varicella / Zoster","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-provarix-sinovac-dalian-vaccine-technology-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07-15 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bnt113-biontech-se","name":"BNT113","developer":"BioNTech SE","targetDisease":"HPV","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-bnt113-biontech-se.html","expectedMilestone":"Primary completion (most advanced trial): 2029-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-01"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-02"},"slow":{"submission":"2030-10","decision":"2032-01","routine_use":"2032-09"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-04","routine_use":"2030-05"},"typical":{"submission":"2030-01","decision":"2031-03","routine_use":"2031-09"},"slow":{"submission":"2030-10","decision":"2032-06","routine_use":"2033-12"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-03"},"slow":{"submission":"2030-10","decision":"2032-01","routine_use":"2033-01"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-dtpa-glaxosmithkline","name":"dTpa","developer":"GlaxoSmithKline","targetDisease":"Diphtheria / Tetanus / Pertussis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"dtap-vaccine.html","page":"/pipeline/ctgov-dtpa-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-11 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-dtpa-vaccine-glaxosmithkline","name":"dTpa vaccine","developer":"GlaxoSmithKline","targetDisease":"Diphtheria / Tetanus / Pertussis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"dtap-vaccine.html","page":"/pipeline/ctgov-dtpa-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-10-14 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-sinovac-rabies-vaccine-sinovac-biotech-co-ltd","name":"Sinovac rabies vaccine","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Rabies","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rabies-vaccine.html","page":"/pipeline/ctgov-sinovac-rabies-vaccine-sinovac-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-09-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-walvax-pcv13-tt-walvax-biotechnology-co-ltd","name":"Pfizer PCV13","developer":"Walvax Biotechnology Co., Ltd.","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-walvax-pcv13-tt-walvax-biotechnology-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2025-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-batch-1-of-group-acyw135-meningococcal-conjugate-vaccine-crm197-","name":"batch 2 of MCV4","developer":"CanSino Biologics Inc.","targetDisease":"Meningococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-batch-1-of-group-acyw135-meningococcal-conjugate-vaccine-crm197-.html","expectedMilestone":"Primary completion (most advanced trial): 2024-07-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2024-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2024-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2024-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rotavac-5d-bharat-biotech-international-limited","name":"ROTAVAC 5D","developer":"Bharat Biotech International Limited","targetDisease":"Rotavirus","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rotavirus-vaccine.html","page":"/pipeline/ctgov-rotavac-5d-bharat-biotech-international-limited.html","expectedMilestone":"Primary completion (most advanced trial): 2025-01-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-2-doses-of-vaccine-quadrivalent-recombinant-human-papillomavirus","name":"2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)","developer":"National Vaccine and Serum Institute, China","targetDisease":"HPV","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-2-doses-of-vaccine-quadrivalent-recombinant-human-papillomavirus.html","expectedMilestone":"Primary completion (most advanced trial): 2032-07 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-10","decision":"2033-04","routine_use":"2033-04"},"typical":{"submission":"2033-04","decision":"2034-02","routine_use":"2034-05"},"slow":{"submission":"2034-01","decision":"2035-04","routine_use":"2035-12"}},"anchor":"2032-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-10","decision":"2033-07","routine_use":"2033-08"},"typical":{"submission":"2033-04","decision":"2034-06","routine_use":"2034-12"},"slow":{"submission":"2034-01","decision":"2035-09","routine_use":"2037-03"}},"anchor":"2032-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-10","decision":"2033-04","routine_use":"2033-05"},"typical":{"submission":"2033-04","decision":"2034-02","routine_use":"2034-06"},"slow":{"submission":"2034-01","decision":"2035-04","routine_use":"2036-04"}},"anchor":"2032-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rsvpref3-oa-investigational-vaccine-glaxosmithkline","name":"RSVPreF3 OA investigational vaccine","developer":"GlaxoSmithKline","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsvpref3-oa-investigational-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2022-06-06 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2022-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2022-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2022-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-cervavac-as-three-dose-regimen-serum-institute-of-india-pvt-ltd","name":"Cervavac as two dose regimen","developer":"Serum Institute of India Pvt. Ltd.","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-cervavac-as-three-dose-regimen-serum-institute-of-india-pvt-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pfizer-bivalent-covid-19-vaccine-monash-university","name":"Moderna Bivalent mRNA vaccine","developer":"Monash University","targetDisease":"COVID-19","platform":"mRNA","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-pfizer-bivalent-covid-19-vaccine-monash-university.html","expectedMilestone":"Primary completion (most advanced trial): 2026-06-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bivalent-moderna-murdoch-childrens-research-institute","name":"Novavax","developer":"Murdoch Childrens Research Institute","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-bivalent-moderna-murdoch-childrens-research-institute.html","expectedMilestone":"Primary completion (most advanced trial): 2024-10-13 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2024-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2024-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2024-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-menacyw-conjugate-vaccine-sanofi","name":"MenAC conjugate vaccine","developer":"Sanofi","targetDisease":"Meningococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-menacyw-conjugate-vaccine-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2026-05-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-hz-su-vaccine-glaxosmithkline","name":"HZ/su vaccine","developer":"GlaxoSmithKline","targetDisease":"Varicella / Zoster","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-hz-su-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2027-08-23 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-11","decision":"2028-05","routine_use":"2028-05"},"typical":{"submission":"2028-05","decision":"2029-03","routine_use":"2029-06"},"slow":{"submission":"2029-02","decision":"2030-05","routine_use":"2031-01"}},"anchor":"2027-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-11","decision":"2028-08","routine_use":"2028-09"},"typical":{"submission":"2028-05","decision":"2029-07","routine_use":"2030-01"},"slow":{"submission":"2029-02","decision":"2030-10","routine_use":"2032-04"}},"anchor":"2027-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-11","decision":"2028-05","routine_use":"2028-06"},"typical":{"submission":"2028-05","decision":"2029-03","routine_use":"2029-07"},"slow":{"submission":"2029-02","decision":"2030-05","routine_use":"2031-05"}},"anchor":"2027-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxo","name":"Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Meningococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxo.html","expectedMilestone":"Primary completion (most advanced trial): 2023-03-09 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2023-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2023-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2023-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bnt162b2-vaccine-biontech-se","name":"BNT162b2 Vaccine","developer":"BioNTech SE","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-bnt162b2-vaccine-biontech-se.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pcv21-vaccine-sanofi-pasteur-a-sanofi-company","name":"RotaTeq","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pcv21-vaccine-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2027-05-17 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-08","decision":"2028-02","routine_use":"2028-02"},"typical":{"submission":"2028-02","decision":"2028-12","routine_use":"2029-03"},"slow":{"submission":"2028-11","decision":"2030-02","routine_use":"2030-10"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-08","decision":"2028-05","routine_use":"2028-06"},"typical":{"submission":"2028-02","decision":"2029-04","routine_use":"2029-10"},"slow":{"submission":"2028-11","decision":"2030-07","routine_use":"2032-01"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-08","decision":"2028-02","routine_use":"2028-03"},"typical":{"submission":"2028-02","decision":"2028-12","routine_use":"2029-04"},"slow":{"submission":"2028-11","decision":"2030-02","routine_use":"2031-02"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bnt162b2-2025-2026-formulation-biontech-se","name":"BNT162b2 (2025/2026 formulation)","developer":"BioNTech SE","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-bnt162b2-2025-2026-formulation-biontech-se.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-c-difficile-vaccine-pfizer","name":"C.difficile vaccine","developer":"Pfizer","targetDisease":"Clostridioides Difficile Associated Disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-c-difficile-vaccine-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2028-12-11 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-09"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-10"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-05"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2029-09","decision":"2030-11","routine_use":"2031-05"},"slow":{"submission":"2030-06","decision":"2032-02","routine_use":"2033-08"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-10"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-11"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-09"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-v181-merck-sharp-dohme-llc","name":"V181","developer":"Merck Sharp & Dohme LLC","targetDisease":"Dengue","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-v181-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2031-10-24 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-01","decision":"2032-07","routine_use":"2032-07"},"typical":{"submission":"2032-07","decision":"2033-05","routine_use":"2033-08"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-03"}},"anchor":"2031-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-01","decision":"2032-10","routine_use":"2032-11"},"typical":{"submission":"2032-07","decision":"2033-09","routine_use":"2034-03"},"slow":{"submission":"2033-04","decision":"2034-12","routine_use":"2036-06"}},"anchor":"2031-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-01","decision":"2032-07","routine_use":"2032-08"},"typical":{"submission":"2032-07","decision":"2033-05","routine_use":"2033-09"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-07"}},"anchor":"2031-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bivalent-enterovirus-vaccine-vero-cell-inactivated-sinovac-biote","name":"Enterovirus Type 71 Vaccine (Vero Cell), Inactivated","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Hand, Foot, and Mouth Disease（HFMD)","platform":"Inactivated","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-bivalent-enterovirus-vaccine-vero-cell-inactivated-sinovac-biote.html","expectedMilestone":"Primary completion (most advanced trial): 2025-11-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-chikv-vlp-vaccine-booster-bavarian-nordic","name":"Placebo booster","developer":"Bavarian Nordic","targetDisease":"Chikungunya","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-chikv-vlp-vaccine-booster-bavarian-nordic.html","expectedMilestone":"Primary completion (most advanced trial): 2028-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-07","decision":"2029-01","routine_use":"2029-01"},"typical":{"submission":"2029-01","decision":"2029-11","routine_use":"2030-02"},"slow":{"submission":"2029-10","decision":"2031-01","routine_use":"2031-09"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-07","decision":"2029-04","routine_use":"2029-05"},"typical":{"submission":"2029-01","decision":"2030-03","routine_use":"2030-09"},"slow":{"submission":"2029-10","decision":"2031-06","routine_use":"2032-12"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-07","decision":"2029-01","routine_use":"2029-02"},"typical":{"submission":"2029-01","decision":"2029-11","routine_use":"2030-03"},"slow":{"submission":"2029-10","decision":"2031-01","routine_use":"2032-01"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-durvalumab-medi4736-astrazeneca","name":"Durvalumab (MEDI4736)","developer":"AstraZeneca","targetDisease":"Tuberculosis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-durvalumab-medi4736-astrazeneca.html","expectedMilestone":"Primary completion (most advanced trial): 2025-04-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-ofatumumab-novartis-pharmaceuticals","name":"Ofatumumab","developer":"Novartis Pharmaceuticals","targetDisease":"Relapsing Multiple Sclerosis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-ofatumumab-novartis-pharmaceuticals.html","expectedMilestone":"Primary completion (most advanced trial): 2028-09-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-12","decision":"2029-06","routine_use":"2029-06"},"typical":{"submission":"2029-06","decision":"2030-04","routine_use":"2030-07"},"slow":{"submission":"2030-03","decision":"2031-06","routine_use":"2032-02"}},"anchor":"2028-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-12","decision":"2029-09","routine_use":"2029-10"},"typical":{"submission":"2029-06","decision":"2030-08","routine_use":"2031-02"},"slow":{"submission":"2030-03","decision":"2031-11","routine_use":"2033-05"}},"anchor":"2028-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-12","decision":"2029-06","routine_use":"2029-07"},"typical":{"submission":"2029-06","decision":"2030-04","routine_use":"2030-08"},"slow":{"submission":"2030-03","decision":"2031-06","routine_use":"2032-06"}},"anchor":"2028-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pembrolizumab-merck-sharp-dohme-llc","name":"BCG","developer":"Merck Sharp & Dohme LLC","targetDisease":"Tuberculosis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-pembrolizumab-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-tetravalent-dengue-vaccine-tdv-takeda","name":"Tetravalent Dengue Vaccine (TDV)","developer":"Takeda","targetDisease":"Dengue","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-tetravalent-dengue-vaccine-tdv-takeda.html","expectedMilestone":"Primary completion (most advanced trial): 2026-08-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rsv-mat-glaxosmithkline","name":"RSV MAT","developer":"GlaxoSmithKline","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsv-mat-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2023-11-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-cvncov-vaccine-curevac","name":"CVnCoV Vaccine","developer":"CureVac","targetDisease":"COVID-19","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-cvncov-vaccine-curevac.html","expectedMilestone":"Primary completion (most advanced trial): 2022-01 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-tecemotide-merck-kgaa-darmstadt-germany","name":"Tecemotide","developer":"Merck KGaA, Darmstadt, Germany","targetDisease":"Non-Small Cell Lung Cancer","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-tecemotide-merck-kgaa-darmstadt-germany.html","expectedMilestone":"Primary completion (most advanced trial): 2015-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-trivalent-inactivated-influenza-vaccine-high-dose-sanofi","name":"Trivalent inactivated influenza vaccine","developer":"Sanofi","targetDisease":"Influenza","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-trivalent-inactivated-influenza-vaccine-high-dose-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2011-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-mva-bn-rsv-vaccine-bavarian-nordic","name":"MVA-BN-RSV vaccine","developer":"Bavarian Nordic","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-mva-bn-rsv-vaccine-bavarian-nordic.html","expectedMilestone":"Primary completion (most advanced trial): 2023-06-29 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-measles-mumps-rubella-and-varicella-oka-merck-virus-vaccine-live","name":"M-M-R™ II and Varivax™","developer":"Merck Sharp & Dohme LLC","targetDisease":"Measles / Mumps / Rubella","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"mmr-vaccine.html","page":"/pipeline/ctgov-measles-mumps-rubella-and-varicella-oka-merck-virus-vaccine-live.html","expectedMilestone":"Primary completion (most advanced trial): 2008-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-quadrivalent-influenza-vaccine-high-dose-sanofi-pasteur-a-sanofi","name":"Quadrivalent influenza vaccine, high-dose","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-quadrivalent-influenza-vaccine-high-dose-sanofi-pasteur-a-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2021-06-02 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-undecavalent-pneumococcal-protein-d-conjugate-vaccine-glaxosmith","name":"undecavalent pneumococcal-protein D conjugate vaccine","developer":"GlaxoSmithKline","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-undecavalent-pneumococcal-protein-d-conjugate-vaccine-glaxosmith.html","expectedMilestone":"Primary completion (most advanced trial): 2004-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-c","name":"Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","developer":"CanSino Biologics Inc.","targetDisease":"COVID-19","platform":"Viral vector","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-c.html","expectedMilestone":"Primary completion (most advanced trial): 2023-01-13 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-ad26-protein-pref-rsv-vaccine-janssen-pharmaceutical-k-k","name":"Ad26/protein preF RSV Vaccine","developer":"Janssen Pharmaceutical K.K.","targetDisease":"RSV","platform":"Viral vector","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-ad26-protein-pref-rsv-vaccine-janssen-pharmaceutical-k-k.html","expectedMilestone":"Primary completion (most advanced trial): 2023-03-20 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-quadrivalent-influenza-vaccine-split-virion-inactivated-high-dos","name":"Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Influenza","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-quadrivalent-influenza-vaccine-split-virion-inactivated-high-dos.html","expectedMilestone":"Primary completion (most advanced trial): 2020-05-31 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-pandemrixtm-glaxosmithkline","name":"PandemrixTM","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-pandemrixtm-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2011-02 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-diphtheria-tetanus-pertussis-hepatitis-b-hib-vaccine-glaxosmithk","name":"Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-diphtheria-tetanus-pertussis-hepatitis-b-hib-vaccine-glaxosmithk.html","expectedMilestone":"See linked ClinicalTrials.gov records for primary completion dates","jurisdictions":{}},{"candidateId":"ctgov-hepatitis-b-vaccine-emergent-biosolutions","name":"hepatitis B vaccine","developer":"Emergent BioSolutions","targetDisease":"Hepatitis B","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-b-vaccine.html","page":"/pipeline/ctgov-hepatitis-b-vaccine-emergent-biosolutions.html","expectedMilestone":"Primary completion (most advanced trial): 2011-03-11 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-recombinant-influenza-vaccine-riv4-sanofi-pasteur-a-sanofi-compa","name":"Recombinant influenza vaccine (RIV4)","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Influenza","platform":"Protein / subunit","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-recombinant-influenza-vaccine-riv4-sanofi-pasteur-a-sanofi-compa.html","expectedMilestone":"Primary completion (most advanced trial): 2023-10-03 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-pfizer-biontech-covid-19-vaccine-sunnybrook-health-sciences-cent","name":"MODERNA SARS-CoV-2 Vaccine","developer":"Sunnybrook Health Sciences Centre","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-pfizer-biontech-covid-19-vaccine-sunnybrook-health-sciences-cent.html","expectedMilestone":"Primary completion (most advanced trial): 2022-05-11 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk-pandemic-vaccine-gsk2340272a-glaxosmithkline","name":"GSK pandemic vaccine GSK2340272A","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk-pandemic-vaccine-gsk2340272a-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2011-01-14 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-coformulated-cic-vaccine-novavax","name":"Fluzone HD trivalent","developer":"Novavax","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-coformulated-cic-vaccine-novavax.html","expectedMilestone":"Primary completion (most advanced trial): 2025-11-16 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-tniv-1-and-matrix-m-adjuvant-novavax","name":"tNIV 1 and Matrix-M Adjuvant","developer":"Novavax","targetDisease":"COVID-19","platform":"Protein / subunit","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-tniv-1-and-matrix-m-adjuvant-novavax.html","expectedMilestone":"Primary completion (most advanced trial): 2025-02-04 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-janssen-vaccine-instituto-de-investigaci-n-marqu-s-de-valdecilla","name":"Janssen vaccine","developer":"Instituto de Investigación Marqués de Valdecilla","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-janssen-vaccine-instituto-de-investigaci-n-marqu-s-de-valdecilla.html","expectedMilestone":"Primary completion (most advanced trial): 2021-09-01 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-varivax-vep-merck-sharp-dohme-llc","name":"M-M-R™ II","developer":"Merck Sharp & Dohme LLC","targetDisease":"Varicella / Zoster","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-varivax-vep-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2015-10 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-quadrivalent-human-papillomavirus-types-6-11-16-18-recombinant-v","name":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","developer":"Merck Sharp & Dohme LLC","targetDisease":"HPV","platform":"Protein / subunit","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-quadrivalent-human-papillomavirus-types-6-11-16-18-recombinant-v.html","expectedMilestone":"Primary completion (most advanced trial): 2013-10-01 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-pfizer-biontech-standard-dose-murdoch-childrens-research-institu","name":"AstraZeneca Standard dose","developer":"Murdoch Childrens Research Institute","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-pfizer-biontech-standard-dose-murdoch-childrens-research-institu.html","expectedMilestone":"Primary completion (most advanced trial): 2025-01 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk-s-candidate-influenza-vaccine-1562902a-glaxosmithkline","name":"GSK's candidate influenza vaccine 1562902A","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk-s-candidate-influenza-vaccine-1562902a-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2011-07 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-v212-lot-1-merck-sharp-dohme-llc","name":"V212 Lot 1","developer":"Merck Sharp & Dohme LLC","targetDisease":"Varicella / Zoster","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-v212-lot-1-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2015-03 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-infanrix-ipv-hib-glaxosmithkline","name":"Infanrix-IPV/Hib","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Conjugate vaccine","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-infanrix-ipv-hib-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2018-08-01 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-vla2001-valneva-austria-gmbh","name":"VLA2001","developer":"Valneva Austria GmbH","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-vla2001-valneva-austria-gmbh.html","expectedMilestone":"Primary completion (most advanced trial): 2023-07-31 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-medium-dosage-covid-19-vaccine-inactivated-sinovac-research-and-","name":"High-dosage COVID-19 Vaccine,Inactivated","developer":"Sinovac Research and Development Co., Ltd.","targetDisease":"COVID-19","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-medium-dosage-covid-19-vaccine-inactivated-sinovac-research-and-.html","expectedMilestone":"Primary completion (most advanced trial): 2023-02-20 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-bivalent-recombinant-covid-19-vaccine-adenovirus-type-5-vector-c","name":"mRNA-based COVID-19 vaccine","developer":"CanSino Biologics Inc.","targetDisease":"COVID-19","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-bivalent-recombinant-covid-19-vaccine-adenovirus-type-5-vector-c.html","expectedMilestone":"Primary completion (most advanced trial): 2023-03-30 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-rotavirus-vaccine-live-oral-pentavalent-merck-sharp-dohme-llc","name":"Rotavirus Vaccine, Live, Oral, Pentavalent","developer":"Merck Sharp & Dohme LLC","targetDisease":"Rotavirus","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rotavirus-vaccine.html","page":"/pipeline/ctgov-rotavirus-vaccine-live-oral-pentavalent-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2010-08 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-janssen-ad26-cov2-s-vaccine-mark-stegall","name":"Janssen Ad26.CoV2.S Vaccine","developer":"Mark Stegall","targetDisease":"Kidney Transplant Recipient","platform":"Viral vector","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-janssen-ad26-cov2-s-vaccine-mark-stegall.html","expectedMilestone":"Primary completion (most advanced trial): 2025-02-28 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-cyd-dengue-vaccine-sanofi-pasteur-a-sanofi-company","name":"CYD Dengue Vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Dengue","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-cyd-dengue-vaccine-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2019-12-10 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-ad26-zebov-janssen-vaccines-prevention-b-v","name":"Ad26.ZEBOV","developer":"Janssen Vaccines & Prevention B.V.","targetDisease":"Ebola","platform":"Viral vector","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-ad26-zebov-janssen-vaccines-prevention-b-v.html","expectedMilestone":"Primary completion (most advanced trial): 2021-12-13 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-c-difficile-toxoid-vaccine-sanofi-pasteur-a-sanofi-company","name":"C. difficile Toxoid Vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Clostridium Difficile Infection","platform":"Toxoid","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-c-difficile-toxoid-vaccine-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2018-06-12 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-lv305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jers","name":"G305","developer":"Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","targetDisease":"Synovial Sarcoma","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-lv305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jers.html","expectedMilestone":"Primary completion (most advanced trial): 2018-11-20 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk1572932a-antigen-specific-cancer-immunotherapeutic-glaxosmith","name":"GSK1572932A Antigen-Specific Cancer Immunotherapeutic","developer":"GlaxoSmithKline","targetDisease":"Lung Cancer, Non-Small Cell","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_3","progress_percent":60,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-gsk1572932a-antigen-specific-cancer-immunotherapeutic-glaxosmith.html","expectedMilestone":"Primary completion (most advanced trial): 2013-12-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-yellow-fever-vaccine-produced-on-serum-free-vero-cells-sanofi-pa","name":"Yellow fever vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Yellow fever","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"yellow-fever-vaccine.html","page":"/pipeline/ctgov-yellow-fever-vaccine-produced-on-serum-free-vero-cells-sanofi-pa.html","expectedMilestone":"Primary completion (most advanced trial): 2022-06-24 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2022-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2022-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2022-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-acne-mrna-vaccine-sanofi-pasteur-a-sanofi-company","name":"Acne mRNA vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Acne","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-acne-mrna-vaccine-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2028-11-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-02","decision":"2030-08","routine_use":"2030-08"},"typical":{"submission":"2031-11","decision":"2032-09","routine_use":"2032-12"},"slow":{"submission":"2035-02","decision":"2036-05","routine_use":"2037-01"}},"anchor":"2028-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-02","decision":"2030-11","routine_use":"2030-12"},"typical":{"submission":"2031-11","decision":"2033-01","routine_use":"2033-07"},"slow":{"submission":"2035-02","decision":"2036-10","routine_use":"2038-04"}},"anchor":"2028-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-02","decision":"2030-08","routine_use":"2030-09"},"typical":{"submission":"2031-11","decision":"2032-09","routine_use":"2033-01"},"slow":{"submission":"2035-02","decision":"2036-05","routine_use":"2037-05"}},"anchor":"2028-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1189-modernatx-inc","name":"mRNA-1189","developer":"ModernaTX, Inc.","targetDisease":"EBV","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrna-1189-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2026-10-05 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-ped-hz-su-glaxosmithkline","name":"PED-HZ/su","developer":"GlaxoSmithKline","targetDisease":"Varicella / Zoster","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-ped-hz-su-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-05-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-vaccine-candidate-1-pfizer","name":"TIV1 or TIV2","developer":"Pfizer","targetDisease":"Influenza","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-vaccine-candidate-1-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2027-06-22 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-03","routine_use":"2029-03"},"typical":{"submission":"2030-06","decision":"2031-04","routine_use":"2031-07"},"slow":{"submission":"2033-09","decision":"2034-12","routine_use":"2035-08"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-06","routine_use":"2029-07"},"typical":{"submission":"2030-06","decision":"2031-08","routine_use":"2032-02"},"slow":{"submission":"2033-09","decision":"2035-05","routine_use":"2036-11"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-03","routine_use":"2029-04"},"typical":{"submission":"2030-06","decision":"2031-04","routine_use":"2031-08"},"slow":{"submission":"2033-09","decision":"2034-12","routine_use":"2035-12"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-low-dose-of-ints-tcv-glaxosmithkline","name":"TYPHIBEV","developer":"GlaxoSmithKline","targetDisease":"Typhoid","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"typhoid-vaccine.html","page":"/pipeline/ctgov-low-dose-of-ints-tcv-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2028-04-27 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-01"},"typical":{"submission":"2031-04","decision":"2032-02","routine_use":"2032-05"},"slow":{"submission":"2034-07","decision":"2035-10","routine_use":"2036-06"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-04","routine_use":"2030-05"},"typical":{"submission":"2031-04","decision":"2032-06","routine_use":"2032-12"},"slow":{"submission":"2034-07","decision":"2036-03","routine_use":"2037-09"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2031-04","decision":"2032-02","routine_use":"2032-06"},"slow":{"submission":"2034-07","decision":"2035-10","routine_use":"2036-10"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-recombinant-trivalent-poliomyelitis-vaccine-sf-rvn-cell-vlp-poli","name":"VLP-Polio medium dose","developer":"CanSino Biologics Inc.","targetDisease":"Polio","platform":"Virus-like particle","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"polio-vaccine.html","page":"/pipeline/ctgov-recombinant-trivalent-poliomyelitis-vaccine-sf-rvn-cell-vlp-poli.html","expectedMilestone":"Primary completion (most advanced trial): 2026-10 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rsv-hmpv-v-low-dose-vaccine-glaxosmithkline","name":"hMPV_Y low dose vaccine","developer":"GlaxoSmithKline","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsv-hmpv-v-low-dose-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2029-04-05 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-01","routine_use":"2031-01"},"typical":{"submission":"2032-04","decision":"2033-02","routine_use":"2033-05"},"slow":{"submission":"2035-07","decision":"2036-10","routine_use":"2037-06"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-04","routine_use":"2031-05"},"typical":{"submission":"2032-04","decision":"2033-06","routine_use":"2033-12"},"slow":{"submission":"2035-07","decision":"2037-03","routine_use":"2038-09"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-01","routine_use":"2031-02"},"typical":{"submission":"2032-04","decision":"2033-02","routine_use":"2033-06"},"slow":{"submission":"2035-07","decision":"2036-10","routine_use":"2037-10"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-oral-hexavalent-reassortant-rotavirus-attenuated-live-vaccine-si","name":"Oral hexavalent reassortant rotavirus attenuated live vaccine","developer":"Sinovac Life Sciences Co., Ltd.","targetDisease":"Rotavirus","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rotavirus-vaccine.html","page":"/pipeline/ctgov-oral-hexavalent-reassortant-rotavirus-attenuated-live-vaccine-si.html","expectedMilestone":"Primary completion (most advanced trial): 2026-06-15 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-adjuvanted-rsvpref3-vaccine-glaxosmithkline","name":"Adjuvanted RSVPreF3 vaccine","developer":"GlaxoSmithKline","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-adjuvanted-rsvpref3-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2027-01-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2028-10","routine_use":"2028-10"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-02"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-03"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2029-01","routine_use":"2029-02"},"typical":{"submission":"2030-01","decision":"2031-03","routine_use":"2031-09"},"slow":{"submission":"2033-04","decision":"2034-12","routine_use":"2036-06"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-03"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-07"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-low-dose-experimental-vaccine-sinovac-biotech-co-ltd","name":"Active-controlled vaccine A","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Varicella / Zoster","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-low-dose-experimental-vaccine-sinovac-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-05-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-24-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197-t","name":"PCV24 vaccine (dose H)","developer":"CanSino Biologics Inc.","targetDisease":"Pneumococcal disease","platform":"Conjugate vaccine","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-24-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197-t.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-24 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-02","decision":"2028-08","routine_use":"2028-08"},"typical":{"submission":"2029-11","decision":"2030-09","routine_use":"2030-12"},"slow":{"submission":"2033-02","decision":"2034-05","routine_use":"2035-01"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-02","decision":"2028-11","routine_use":"2028-12"},"typical":{"submission":"2029-11","decision":"2031-01","routine_use":"2031-07"},"slow":{"submission":"2033-02","decision":"2034-10","routine_use":"2036-04"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-02","decision":"2028-08","routine_use":"2028-09"},"typical":{"submission":"2029-11","decision":"2030-09","routine_use":"2031-01"},"slow":{"submission":"2033-02","decision":"2034-05","routine_use":"2035-05"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pentavalent-meningococcal-abcyw-vaccine-sanofi-pasteur-a-sanofi-","name":"MenACYW conjugate vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Meningococcal disease","platform":"Conjugate vaccine","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-pentavalent-meningococcal-abcyw-vaccine-sanofi-pasteur-a-sanofi-.html","expectedMilestone":"Primary completion (most advanced trial): 2027-05-17 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-08","decision":"2029-02","routine_use":"2029-02"},"typical":{"submission":"2030-05","decision":"2031-03","routine_use":"2031-06"},"slow":{"submission":"2033-08","decision":"2034-11","routine_use":"2035-07"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-08","decision":"2029-05","routine_use":"2029-06"},"typical":{"submission":"2030-05","decision":"2031-07","routine_use":"2032-01"},"slow":{"submission":"2033-08","decision":"2035-04","routine_use":"2036-10"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-08","decision":"2029-02","routine_use":"2029-03"},"typical":{"submission":"2030-05","decision":"2031-03","routine_use":"2031-07"},"slow":{"submission":"2033-08","decision":"2034-11","routine_use":"2035-11"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-investigational-hmpv-rsv-vaccine-sanofi-pasteur-a-sanofi-company","name":"Licensed RSV Vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"RSV","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-investigational-hmpv-rsv-vaccine-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2027-01-18 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2028-10","routine_use":"2028-10"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-02"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-03"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2029-01","routine_use":"2029-02"},"typical":{"submission":"2030-01","decision":"2031-03","routine_use":"2031-09"},"slow":{"submission":"2033-04","decision":"2034-12","routine_use":"2036-06"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-03"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-07"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-z-1018-dynavax-technologies-corporation","name":"Z-1018","developer":"Dynavax Technologies Corporation","targetDisease":"Varicella / Zoster","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-z-1018-dynavax-technologies-corporation.html","expectedMilestone":"Primary completion (most advanced trial): 2027-11 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-02","decision":"2029-08","routine_use":"2029-08"},"typical":{"submission":"2030-11","decision":"2031-09","routine_use":"2031-12"},"slow":{"submission":"2034-02","decision":"2035-05","routine_use":"2036-01"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-02","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2030-11","decision":"2032-01","routine_use":"2032-07"},"slow":{"submission":"2034-02","decision":"2035-10","routine_use":"2037-04"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-02","decision":"2029-08","routine_use":"2029-09"},"typical":{"submission":"2030-11","decision":"2031-09","routine_use":"2032-01"},"slow":{"submission":"2034-02","decision":"2035-05","routine_use":"2036-05"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-ints-gmma-dose-c-glaxosmithkline","name":"MenACWY","developer":"GlaxoSmithKline","targetDisease":"Typhoid","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"typhoid-vaccine.html","page":"/pipeline/ctgov-ints-gmma-dose-c-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-09-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pandemic-flu-h5-ha-mrna-sd2-vaccine-sanofi","name":"Pandemic flu H5 HA mRNA SD2 vaccine","developer":"Sanofi","targetDisease":"Influenza","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-pandemic-flu-h5-ha-mrna-sd2-vaccine-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-03","decision":"2028-09","routine_use":"2028-09"},"typical":{"submission":"2029-12","decision":"2030-10","routine_use":"2031-01"},"slow":{"submission":"2033-03","decision":"2034-06","routine_use":"2035-02"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-03","decision":"2028-12","routine_use":"2029-01"},"typical":{"submission":"2029-12","decision":"2031-02","routine_use":"2031-08"},"slow":{"submission":"2033-03","decision":"2034-11","routine_use":"2036-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-03","decision":"2028-09","routine_use":"2028-10"},"typical":{"submission":"2029-12","decision":"2030-10","routine_use":"2031-02"},"slow":{"submission":"2033-03","decision":"2034-06","routine_use":"2035-06"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-azd4117-astrazeneca","name":"AZD4117","developer":"AstraZeneca","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-azd4117-astrazeneca.html","expectedMilestone":"Primary completion (most advanced trial): 2026-01-28 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-0-5-ml-of-the-low-dose-vax-31-vaxcyte-inc","name":"0.5 mL of the low dose VAX-31","developer":"Vaxcyte, Inc.","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-0-5-ml-of-the-low-dose-vax-31-vaxcyte-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-09"},"typical":{"submission":"2030-12","decision":"2031-10","routine_use":"2032-01"},"slow":{"submission":"2034-03","decision":"2035-06","routine_use":"2036-02"}},"anchor":"2027-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2030-12","decision":"2032-02","routine_use":"2032-08"},"slow":{"submission":"2034-03","decision":"2035-11","routine_use":"2037-05"}},"anchor":"2027-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-10"},"typical":{"submission":"2030-12","decision":"2031-10","routine_use":"2032-02"},"slow":{"submission":"2034-03","decision":"2035-06","routine_use":"2036-06"}},"anchor":"2027-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-flu-mrna-formulation-b1-glaxosmithkline","name":"Flu mRNA(Formulation A)","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-flu-mrna-formulation-b1-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1468-modernatx-inc","name":"mRNA-1468","developer":"ModernaTX, Inc.","targetDisease":"Varicella / Zoster","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-mrna-1468-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2026-06-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1195-modernatx-inc","name":"mRNA-1195","developer":"ModernaTX, Inc.","targetDisease":"Multiple Sclerosis","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrna-1195-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2029-01-08 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-04","decision":"2030-10","routine_use":"2030-10"},"typical":{"submission":"2032-01","decision":"2032-11","routine_use":"2033-02"},"slow":{"submission":"2035-04","decision":"2036-07","routine_use":"2037-03"}},"anchor":"2029-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-04","decision":"2031-01","routine_use":"2031-02"},"typical":{"submission":"2032-01","decision":"2033-03","routine_use":"2033-09"},"slow":{"submission":"2035-04","decision":"2036-12","routine_use":"2038-06"}},"anchor":"2029-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-04","decision":"2030-10","routine_use":"2030-11"},"typical":{"submission":"2032-01","decision":"2032-11","routine_use":"2033-03"},"slow":{"submission":"2035-04","decision":"2036-07","routine_use":"2037-07"}},"anchor":"2029-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bnt166a-biontech-se","name":"BNT166a","developer":"BioNTech SE","targetDisease":"Mpox","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-bnt166a-biontech-se.html","expectedMilestone":"Primary completion (most advanced trial): 2027-06 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-03","routine_use":"2029-03"},"typical":{"submission":"2030-06","decision":"2031-04","routine_use":"2031-07"},"slow":{"submission":"2033-09","decision":"2034-12","routine_use":"2035-08"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-06","routine_use":"2029-07"},"typical":{"submission":"2030-06","decision":"2031-08","routine_use":"2032-02"},"slow":{"submission":"2033-09","decision":"2035-05","routine_use":"2036-11"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-03","routine_use":"2029-04"},"typical":{"submission":"2030-06","decision":"2031-04","routine_use":"2031-08"},"slow":{"submission":"2033-09","decision":"2034-12","routine_use":"2035-12"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rf1v-1018-dynavax-technologies-corporation","name":"rF1V-1018","developer":"Dynavax Technologies Corporation","targetDisease":"Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-rf1v-1018-dynavax-technologies-corporation.html","expectedMilestone":"Primary completion (most advanced trial): 2027-01-29 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2028-10","routine_use":"2028-10"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-02"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-03"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2029-01","routine_use":"2029-02"},"typical":{"submission":"2030-01","decision":"2031-03","routine_use":"2031-09"},"slow":{"submission":"2033-04","decision":"2034-12","routine_use":"2036-06"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-04","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-03"},"slow":{"submission":"2033-04","decision":"2034-07","routine_use":"2035-07"}},"anchor":"2027-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-chlamydia-mrna-vaccine-sanofi","name":"Chlamydia mRNA Vaccine","developer":"Sanofi","targetDisease":"Chlamydia Trachomatis Immunization","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-chlamydia-mrna-vaccine-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2028-01-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-04","decision":"2029-10","routine_use":"2029-10"},"typical":{"submission":"2031-01","decision":"2031-11","routine_use":"2032-02"},"slow":{"submission":"2034-04","decision":"2035-07","routine_use":"2036-03"}},"anchor":"2028-01","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-04","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2031-01","decision":"2032-03","routine_use":"2032-09"},"slow":{"submission":"2034-04","decision":"2035-12","routine_use":"2037-06"}},"anchor":"2028-01","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-04","decision":"2029-10","routine_use":"2029-11"},"typical":{"submission":"2031-01","decision":"2031-11","routine_use":"2032-03"},"slow":{"submission":"2034-04","decision":"2035-07","routine_use":"2036-07"}},"anchor":"2028-01","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1982-modernatx-inc","name":"mRNA-1982","developer":"ModernaTX, Inc.","targetDisease":"Lyme disease","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrna-1982-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2028-11-09 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-02","decision":"2030-08","routine_use":"2030-08"},"typical":{"submission":"2031-11","decision":"2032-09","routine_use":"2032-12"},"slow":{"submission":"2035-02","decision":"2036-05","routine_use":"2037-01"}},"anchor":"2028-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-02","decision":"2030-11","routine_use":"2030-12"},"typical":{"submission":"2031-11","decision":"2033-01","routine_use":"2033-07"},"slow":{"submission":"2035-02","decision":"2036-10","routine_use":"2038-04"}},"anchor":"2028-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-02","decision":"2030-08","routine_use":"2030-09"},"typical":{"submission":"2031-11","decision":"2032-09","routine_use":"2033-01"},"slow":{"submission":"2035-02","decision":"2036-05","routine_use":"2037-05"}},"anchor":"2028-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-as01-adjuvant-0-5-ml-intramuscular-singapore-general-hospital","name":"YF17D (Stamaril, Sanofi-Pasteur)","developer":"Singapore General Hospital","targetDisease":"Immune System Responses and Trained Immunity After AS01 Administration","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-as01-adjuvant-0-5-ml-intramuscular-singapore-general-hospital.html","expectedMilestone":"Primary completion (most advanced trial): 2029-02-28 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-05","decision":"2030-11","routine_use":"2030-11"},"typical":{"submission":"2032-02","decision":"2032-12","routine_use":"2033-03"},"slow":{"submission":"2035-05","decision":"2036-08","routine_use":"2037-04"}},"anchor":"2029-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-05","decision":"2031-02","routine_use":"2031-03"},"typical":{"submission":"2032-02","decision":"2033-04","routine_use":"2033-10"},"slow":{"submission":"2035-05","decision":"2037-01","routine_use":"2038-07"}},"anchor":"2029-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-05","decision":"2030-11","routine_use":"2030-12"},"typical":{"submission":"2032-02","decision":"2032-12","routine_use":"2033-04"},"slow":{"submission":"2035-05","decision":"2036-08","routine_use":"2037-08"}},"anchor":"2029-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-rts-s-as01e-vaccine-glaxosmithkline","name":"RTS,S/AS01E vaccine","developer":"GlaxoSmithKline","targetDisease":"Malaria","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-rts-s-as01e-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2027-04-23 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-07","decision":"2029-01","routine_use":"2029-01"},"typical":{"submission":"2030-04","decision":"2031-02","routine_use":"2031-05"},"slow":{"submission":"2033-07","decision":"2034-10","routine_use":"2035-06"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-07","decision":"2029-04","routine_use":"2029-05"},"typical":{"submission":"2030-04","decision":"2031-06","routine_use":"2031-12"},"slow":{"submission":"2033-07","decision":"2035-03","routine_use":"2036-09"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-07","decision":"2029-01","routine_use":"2029-02"},"typical":{"submission":"2030-04","decision":"2031-02","routine_use":"2031-06"},"slow":{"submission":"2033-07","decision":"2034-10","routine_use":"2035-10"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-zigakibart-novartis-pharmaceuticals","name":"zigakibart","developer":"Novartis Pharmaceuticals","targetDisease":"Immunoglobulin A Nephropathy (IgAN)","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-zigakibart-novartis-pharmaceuticals.html","expectedMilestone":"Primary completion (most advanced trial): 2030-07-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-10","decision":"2032-04","routine_use":"2032-04"},"typical":{"submission":"2033-07","decision":"2034-05","routine_use":"2034-08"},"slow":{"submission":"2036-10","decision":"2038-01","routine_use":"2038-09"}},"anchor":"2030-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-10","decision":"2032-07","routine_use":"2032-08"},"typical":{"submission":"2033-07","decision":"2034-09","routine_use":"2035-03"},"slow":{"submission":"2036-10","decision":"2038-06","routine_use":"2039-12"}},"anchor":"2030-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-10","decision":"2032-04","routine_use":"2032-05"},"typical":{"submission":"2033-07","decision":"2034-05","routine_use":"2034-09"},"slow":{"submission":"2036-10","decision":"2038-01","routine_use":"2039-01"}},"anchor":"2030-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-influenza-vaccine-sequiris-fluad-quad-central-adelaide-local-hea","name":"RSV vaccine (Pfizer Abrysvo)","developer":"Central Adelaide Local Health Network Incorporated","targetDisease":"Vaccine Immune Response","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-influenza-vaccine-sequiris-fluad-quad-central-adelaide-local-hea.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-altsonflex1-2-3-glaxosmithkline","name":"Menveo","developer":"GlaxoSmithKline","targetDisease":"Diarrhoea","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-altsonflex1-2-3-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2028-10-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-01","decision":"2030-07","routine_use":"2030-07"},"typical":{"submission":"2031-10","decision":"2032-08","routine_use":"2032-11"},"slow":{"submission":"2035-01","decision":"2036-04","routine_use":"2036-12"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-01","decision":"2030-10","routine_use":"2030-11"},"typical":{"submission":"2031-10","decision":"2032-12","routine_use":"2033-06"},"slow":{"submission":"2035-01","decision":"2036-09","routine_use":"2038-03"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-01","decision":"2030-07","routine_use":"2030-08"},"typical":{"submission":"2031-10","decision":"2032-08","routine_use":"2032-12"},"slow":{"submission":"2035-01","decision":"2036-04","routine_use":"2037-04"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-v540a-2-merck-sharp-dohme-llc","name":"V540A-2","developer":"Merck Sharp & Dohme LLC","targetDisease":"Healthy","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-v540a-2-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2028-04-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-01"},"typical":{"submission":"2031-04","decision":"2032-02","routine_use":"2032-05"},"slow":{"submission":"2034-07","decision":"2035-10","routine_use":"2036-06"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-04","routine_use":"2030-05"},"typical":{"submission":"2031-04","decision":"2032-06","routine_use":"2032-12"},"slow":{"submission":"2034-07","decision":"2036-03","routine_use":"2037-09"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2031-04","decision":"2032-02","routine_use":"2032-06"},"slow":{"submission":"2034-07","decision":"2035-10","routine_use":"2036-10"}},"anchor":"2028-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pfizer-biontech-mrna-covid-19-vaccine-university-of-florida","name":"Pfizer-BioNTech mRNA COVID-19 vaccine","developer":"University of Florida","targetDisease":"Stage 4 NSCLC","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-pfizer-biontech-mrna-covid-19-vaccine-university-of-florida.html","expectedMilestone":"Primary completion (most advanced trial): 2035-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2036-06","decision":"2036-12","routine_use":"2036-12"},"typical":{"submission":"2038-03","decision":"2039-01","routine_use":"2039-04"},"slow":{"submission":"2041-06","decision":"2042-09","routine_use":"2043-05"}},"anchor":"2035-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2036-06","decision":"2037-03","routine_use":"2037-04"},"typical":{"submission":"2038-03","decision":"2039-05","routine_use":"2039-11"},"slow":{"submission":"2041-06","decision":"2043-02","routine_use":"2044-08"}},"anchor":"2035-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2036-06","decision":"2036-12","routine_use":"2037-01"},"typical":{"submission":"2038-03","decision":"2039-01","routine_use":"2039-05"},"slow":{"submission":"2041-06","decision":"2042-09","routine_use":"2043-09"}},"anchor":"2035-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mtbvac-bharat-biotech-international-limited","name":"MTBVAC","developer":"Bharat Biotech International Limited","targetDisease":"Tuberculosis","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mtbvac-bharat-biotech-international-limited.html","expectedMilestone":"Primary completion (most advanced trial): 2025-09-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2025-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2025-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2025-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mva-bn-wev-bavarian-nordic","name":"MVA-BN-WEV","developer":"Bavarian Nordic","targetDisease":"Encephalitis","platform":"Protein / subunit","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mva-bn-wev-bavarian-nordic.html","expectedMilestone":"Primary completion (most advanced trial): 2027-02 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-05","decision":"2028-11","routine_use":"2028-11"},"typical":{"submission":"2030-02","decision":"2030-12","routine_use":"2031-03"},"slow":{"submission":"2033-05","decision":"2034-08","routine_use":"2035-04"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-05","decision":"2029-02","routine_use":"2029-03"},"typical":{"submission":"2030-02","decision":"2031-04","routine_use":"2031-10"},"slow":{"submission":"2033-05","decision":"2035-01","routine_use":"2036-07"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-05","decision":"2028-11","routine_use":"2028-12"},"typical":{"submission":"2030-02","decision":"2030-12","routine_use":"2031-04"},"slow":{"submission":"2033-05","decision":"2034-08","routine_use":"2035-08"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bnt164a1-biontech-se","name":"BNT164a1","developer":"BioNTech SE","targetDisease":"Tuberculosis","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-bnt164a1-biontech-se.html","expectedMilestone":"Primary completion (most advanced trial): 2026-03-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-07"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-11"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2034-12"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-10","routine_use":"2028-11"},"typical":{"submission":"2029-10","decision":"2030-12","routine_use":"2031-06"},"slow":{"submission":"2033-01","decision":"2034-09","routine_use":"2036-03"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-01","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2029-10","decision":"2030-08","routine_use":"2030-12"},"slow":{"submission":"2033-01","decision":"2034-04","routine_use":"2035-04"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-c-difficile-vaccine-previously-studied-formulation-pfizer","name":"C. difficile vaccine formulation 1.","developer":"Pfizer","targetDisease":"Clostridoides Difficile Associated Disease","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-c-difficile-vaccine-previously-studied-formulation-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2031-06-19 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-09","decision":"2033-03","routine_use":"2033-03"},"typical":{"submission":"2034-06","decision":"2035-04","routine_use":"2035-07"},"slow":{"submission":"2037-09","decision":"2038-12","routine_use":"2039-08"}},"anchor":"2031-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-09","decision":"2033-06","routine_use":"2033-07"},"typical":{"submission":"2034-06","decision":"2035-08","routine_use":"2036-02"},"slow":{"submission":"2037-09","decision":"2039-05","routine_use":"2040-11"}},"anchor":"2031-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-09","decision":"2033-03","routine_use":"2033-04"},"typical":{"submission":"2034-06","decision":"2035-04","routine_use":"2035-08"},"slow":{"submission":"2037-09","decision":"2038-12","routine_use":"2039-12"}},"anchor":"2031-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-10-g-of-r21-with-50-g-matrix-m1-serum-institute-of-india-pvt-ltd","name":"RABIVAX-S","developer":"Serum Institute of India Pvt. Ltd.","targetDisease":"Malaria","platform":"Protein / subunit","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-10-g-of-r21-with-50-g-matrix-m1-serum-institute-of-india-pvt-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2027-11 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-02","decision":"2029-08","routine_use":"2029-08"},"typical":{"submission":"2030-11","decision":"2031-09","routine_use":"2031-12"},"slow":{"submission":"2034-02","decision":"2035-05","routine_use":"2036-01"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-02","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2030-11","decision":"2032-01","routine_use":"2032-07"},"slow":{"submission":"2034-02","decision":"2035-10","routine_use":"2037-04"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-02","decision":"2029-08","routine_use":"2029-09"},"typical":{"submission":"2030-11","decision":"2031-09","routine_use":"2032-01"},"slow":{"submission":"2034-02","decision":"2035-05","routine_use":"2036-05"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-4157-modernatx-inc","name":"mRNA-4157","developer":"ModernaTX, Inc.","targetDisease":"Melanoma","platform":"mRNA","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrna-4157-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2032-11-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2034-02","decision":"2034-08","routine_use":"2034-08"},"typical":{"submission":"2035-11","decision":"2036-09","routine_use":"2036-12"},"slow":{"submission":"2039-02","decision":"2040-05","routine_use":"2041-01"}},"anchor":"2032-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2034-02","decision":"2034-11","routine_use":"2034-12"},"typical":{"submission":"2035-11","decision":"2037-01","routine_use":"2037-07"},"slow":{"submission":"2039-02","decision":"2040-10","routine_use":"2042-04"}},"anchor":"2032-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2034-02","decision":"2034-08","routine_use":"2034-09"},"typical":{"submission":"2035-11","decision":"2036-09","routine_use":"2037-01"},"slow":{"submission":"2039-02","decision":"2040-05","routine_use":"2041-05"}},"anchor":"2032-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-jynneos-bavarian-nordic","name":"Jynneos","developer":"Bavarian Nordic","targetDisease":"Mpox","platform":"Biological (unspecified platform)","stage":"phase_2","stage_label":"Phase 2","stage_at_discontinuation":null,"progress_percent":35,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-jynneos-bavarian-nordic.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-02","decision":"2028-08","routine_use":"2028-08"},"typical":{"submission":"2029-11","decision":"2030-09","routine_use":"2030-12"},"slow":{"submission":"2033-02","decision":"2034-05","routine_use":"2035-01"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-02","decision":"2028-11","routine_use":"2028-12"},"typical":{"submission":"2029-11","decision":"2031-01","routine_use":"2031-07"},"slow":{"submission":"2033-02","decision":"2034-10","routine_use":"2036-04"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-02","decision":"2028-08","routine_use":"2028-09"},"typical":{"submission":"2029-11","decision":"2030-09","routine_use":"2031-01"},"slow":{"submission":"2033-02","decision":"2034-05","routine_use":"2035-05"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-cv9104-curevac","name":"CV9104","developer":"CureVac","targetDisease":"Prostate Carcinoma","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-cv9104-curevac.html","expectedMilestone":"Primary completion (most advanced trial): 2016-04 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-moderna-mrna-1273-national-institute-of-allergy-and-infectious-d","name":"Moderna mRNA-1273","developer":"National Institute of Allergy and Infectious Diseases (NIAID)","targetDisease":"COVID-19","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-moderna-mrna-1273-national-institute-of-allergy-and-infectious-d.html","expectedMilestone":"Primary completion (most advanced trial): 2023-06-22 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-meningococcal-b-rlp2086-vaccine-pfizer","name":"meningococcal B rLP2086 vaccine","developer":"Pfizer","targetDisease":"Meningococcal disease","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-meningococcal-b-rlp2086-vaccine-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2009-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-equine-covid-19-antiserum-bharat-serums-and-vaccines-limited","name":"Equine COVID-19 Antiserum","developer":"Bharat Serums and Vaccines Limited","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-equine-covid-19-antiserum-bharat-serums-and-vaccines-limited.html","expectedMilestone":"Primary completion (most advanced trial): 2022-05-25 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-v591-merck-sharp-dohme-llc","name":"V591","developer":"Merck Sharp & Dohme LLC","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-v591-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2021-03-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-multivalent-pfizer","name":"Prevnar 13","developer":"Pfizer","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-multivalent-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2020-11-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-chad155-hii-hbv-low-dose-formulation-glaxosmithkline","name":"MVA-HBV low dose formulation","developer":"GlaxoSmithKline","targetDisease":"Hepatitis B","platform":"Viral vector","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-b-vaccine.html","page":"/pipeline/ctgov-chad155-hii-hbv-low-dose-formulation-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2024-10-07 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk2202083a-vaccine-glaxosmithkline","name":"GSK2202083A vaccine","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk2202083a-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2009-06-25 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-rsv-pref-based-vaccine-janssen-vaccines-prevention-b-v","name":"RSV preF-based Vaccine","developer":"Janssen Vaccines & Prevention B.V.","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsv-pref-based-vaccine-janssen-vaccines-prevention-b-v.html","expectedMilestone":"Primary completion (most advanced trial): 2023-01-16 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-menabcwy-pfizer","name":"Bexsero","developer":"Pfizer","targetDisease":"Meningococcal disease","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-menabcwy-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2022-09-15 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-sabin-based-inactivated-poliomyelitis-vaccine-sipv-takeda","name":"Reference IPV","developer":"Takeda","targetDisease":"Polio","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"polio-vaccine.html","page":"/pipeline/ctgov-sabin-based-inactivated-poliomyelitis-vaccine-sipv-takeda.html","expectedMilestone":"Primary completion (most advanced trial): 2018-04-03 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-nanoflu-quad-niv-novavax","name":"Fluzone HD","developer":"Novavax","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-nanoflu-quad-niv-novavax.html","expectedMilestone":"Primary completion (most advanced trial): 2019-04-26 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk2340272a-gsk-biologicals-investigational-influenza-pandemic-v","name":"GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk2340272a-gsk-biologicals-investigational-influenza-pandemic-v.html","expectedMilestone":"Primary completion (most advanced trial): 2010-11-25 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-mrna-1273-214-modernatx-inc","name":"mRNA-1273.214","developer":"ModernaTX, Inc.","targetDisease":"COVID-19","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-mrna-1273-214-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2024-11-15 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk-bio-s-influenza-vaccine-gsk2584786a-different-formulations-g","name":"GSK Bio's influenza vaccine GSK2584786A, different formulations","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk-bio-s-influenza-vaccine-gsk2584786a-different-formulations-g.html","expectedMilestone":"Primary completion (most advanced trial): 2011-03-22 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-sars-cov-2-mrna-vaccine-formulation-1-sanofi-pasteur-a-sanofi-co","name":"Placebo (0.9% normal saline)","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"COVID-19","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-sars-cov-2-mrna-vaccine-formulation-1-sanofi-pasteur-a-sanofi-co.html","expectedMilestone":"Primary completion (most advanced trial): 2022-06-27 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-1018-iss-hbsag-single-dynavax-technologies-corporation","name":"1018 ISS-HBsAg-Single","developer":"Dynavax Technologies Corporation","targetDisease":"Hepatitis B","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-b-vaccine.html","page":"/pipeline/ctgov-1018-iss-hbsag-single-dynavax-technologies-corporation.html","expectedMilestone":"Primary completion (most advanced trial): 2008-08 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-v502-merck-sharp-dohme-llc","name":"V502","developer":"Merck Sharp & Dohme LLC","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-v502-merck-sharp-dohme-llc.html","expectedMilestone":"See linked ClinicalTrials.gov records for primary completion dates","jurisdictions":{}},{"candidateId":"ctgov-vaccine-sanofi-a-h1n1-15-ug-trivalent-instituto-nacional-de-salu","name":"Vaccine Sanofi A(H1N1) 7.5 ug","developer":"Instituto Nacional de Salud Publica, Mexico","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-vaccine-sanofi-a-h1n1-15-ug-trivalent-instituto-nacional-de-salu.html","expectedMilestone":"Primary completion (most advanced trial): 2010-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-influenza-surface-antigen-inactivated-vaccine-novartis","name":"influenza surface antigen inactivated vaccine","developer":"Novartis","targetDisease":"Influenza","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-influenza-surface-antigen-inactivated-vaccine-novartis.html","expectedMilestone":"See linked ClinicalTrials.gov records for primary completion dates","jurisdictions":{}},{"candidateId":"ctgov-gsk-influenza-virus-h5n1-vaccine-1557484a-glaxosmithkline","name":"GSK influenza virus H5N1 vaccine 1557484A","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk-influenza-virus-h5n1-vaccine-1557484a-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2013-02 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-rsv-vaccine-gsk3003891a-formulation-1-glaxosmithkline","name":"RSV vaccine (GSK3003891A) formulation 1","developer":"GlaxoSmithKline","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-rsv-vaccine-gsk3003891a-formulation-1-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2017-07-14 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-251154-vaccine-glaxosmithkline","name":"Synflorix™","developer":"GlaxoSmithKline","targetDisease":"Rotavirus","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rotavirus-vaccine.html","page":"/pipeline/ctgov-251154-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2012-08 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk-biologicals-investigational-h1n1-influenza-vaccine-gsk234027","name":"GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk-biologicals-investigational-h1n1-influenza-vaccine-gsk234027.html","expectedMilestone":"Primary completion (most advanced trial): 2010-10 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-covid-19-vaccine-vero-cell-inactivated-medium-dose-sinovac-resea","name":"COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)","developer":"Sinovac Research and Development Co., Ltd.","targetDisease":"COVID-19","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-covid-19-vaccine-vero-cell-inactivated-medium-dose-sinovac-resea.html","expectedMilestone":"Primary completion (most advanced trial): 2022-03-10 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-sii-b-1-351-novavax","name":"SII B.1.351","developer":"Novavax","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-sii-b-1-351-novavax.html","expectedMilestone":"Primary completion (most advanced trial): 2022-08 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-medium-dose-covid-19-vaccine-vero-cell-inactivated-sinovac-resea","name":"High-dose COVID-19 Vaccine(Vero Cell),Inactivated","developer":"Sinovac Research and Development Co., Ltd.","targetDisease":"COVID-19","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-medium-dose-covid-19-vaccine-vero-cell-inactivated-sinovac-resea.html","expectedMilestone":"Primary completion (most advanced trial): 2023-01-15 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk-biologicals-investigational-tb-vaccine-gsk-692342-glaxosmith","name":"GSK Biologicals' investigational TB vaccine GSK 692342","developer":"GlaxoSmithKline","targetDisease":"Tuberculosis","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-gsk-biologicals-investigational-tb-vaccine-gsk-692342-glaxosmith.html","expectedMilestone":"Primary completion (most advanced trial): 2014-04-01 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-immunotherapeutic-gsk2132231a-glaxosmithkline","name":"Immunotherapeutic GSK2132231A","developer":"GlaxoSmithKline","targetDisease":"Melanoma","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-immunotherapeutic-gsk2132231a-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2014-11-17 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-cmb305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jer","name":"CMB305","developer":"Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","targetDisease":"Sarcoma","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-cmb305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jer.html","expectedMilestone":"Primary completion (most advanced trial): 2019-02-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-mrkad5-hiv-1-gag-pol-nef-4-x-10-9-ad5-vg-dose-v520-merck-sharp-d","name":"MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)","developer":"Merck Sharp & Dohme LLC","targetDisease":"HIV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrkad5-hiv-1-gag-pol-nef-4-x-10-9-ad5-vg-dose-v520-merck-sharp-d.html","expectedMilestone":"Primary completion (most advanced trial): 2008-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-acam1000-sanofi-pasteur-a-sanofi-company","name":"ACAM1000","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Smallpox","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-acam1000-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2003-03 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-acc-001-qs21-3mcg-pfizer","name":"ACC-001+ QS21 (3mcg)","developer":"Pfizer","targetDisease":"Alzheimer Disease","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-acc-001-qs21-3mcg-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2013-12 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-alvac-2-melanoma-multi-antigen-therapeutic-vaccine-sanofi-pasteu","name":"Intron A, Interferon alpha -2b","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Melanoma","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-alvac-2-melanoma-multi-antigen-therapeutic-vaccine-sanofi-pasteu.html","expectedMilestone":"Primary completion (most advanced trial): 2010-04 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-staphylococcus-aureus-4-antigen-sa4ag-vaccine-pfizer","name":"Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine","developer":"Pfizer","targetDisease":"Staphylococcal Vaccine","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-staphylococcus-aureus-4-antigen-sa4ag-vaccine-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2019-06-26 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-acc-001-pfizer","name":"ACC-001","developer":"Pfizer","targetDisease":"Alzheimer's Disease","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-acc-001-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2013-12 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-trivalent-mrkad5-hiv-1-gag-pol-nef-1-5x10-10-ad-vg-dose-merck-sh","name":"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)","developer":"Merck Sharp & Dohme LLC","targetDisease":"HIV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-trivalent-mrkad5-hiv-1-gag-pol-nef-1-5x10-10-ad-vg-dose-merck-sh.html","expectedMilestone":"Primary completion (most advanced trial): 2007-09 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-amb-a-1-immunostimulatory-oligodeoxyribonucleotide-conjugate-dyn","name":"Histamine base","developer":"Dynavax Technologies Corporation","targetDisease":"Rhinitis, Allergic, Seasonal","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-amb-a-1-immunostimulatory-oligodeoxyribonucleotide-conjugate-dyn.html","expectedMilestone":"Primary completion (most advanced trial): 2007-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-purified-inactivated-zika-virus-vaccine-pizv-takeda","name":"Purified Inactivated Zika Virus Vaccine (PIZV)","developer":"Takeda","targetDisease":"Healthy Volunteers","platform":"Inactivated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-purified-inactivated-zika-virus-vaccine-pizv-takeda.html","expectedMilestone":"Primary completion (most advanced trial): 2024-07-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-400-u-ev71-vaccine-with-adjuvant-sinovac-biotech-co-ltd","name":"400 U EV71 vaccine with adjuvant","developer":"Sinovac Biotech Co., Ltd","targetDisease":"Infection, Viral, Enterovirus","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_2","progress_percent":35,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-400-u-ev71-vaccine-with-adjuvant-sinovac-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2011-11 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-pn-maps30plus-glaxosmithkline","name":"Pn-MAPS30plus","developer":"GlaxoSmithKline","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pn-maps30plus-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2027-02-22 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-01"},"typical":{"submission":"2033-01","decision":"2033-11","routine_use":"2034-02"},"slow":{"submission":"2038-07","decision":"2039-10","routine_use":"2040-06"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-04","routine_use":"2030-05"},"typical":{"submission":"2033-01","decision":"2034-03","routine_use":"2034-09"},"slow":{"submission":"2038-07","decision":"2040-03","routine_use":"2041-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2033-01","decision":"2033-11","routine_use":"2034-03"},"slow":{"submission":"2038-07","decision":"2039-10","routine_use":"2040-10"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-investigational-mrna-seasonal-flu-covid-19-combination-flu-covm-","name":"Licensed Seasonal Influenza Vaccine","developer":"GlaxoSmithKline","targetDisease":"COVID-19","platform":"mRNA","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-investigational-mrna-seasonal-flu-covid-19-combination-flu-covm-.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-01"},"typical":{"submission":"2033-01","decision":"2033-11","routine_use":"2034-02"},"slow":{"submission":"2038-07","decision":"2039-10","routine_use":"2040-06"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-04","routine_use":"2030-05"},"typical":{"submission":"2033-01","decision":"2034-03","routine_use":"2034-09"},"slow":{"submission":"2038-07","decision":"2040-03","routine_use":"2041-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2033-01","decision":"2033-11","routine_use":"2034-03"},"slow":{"submission":"2038-07","decision":"2039-10","routine_use":"2040-10"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-v118c-stage-1-merck-sharp-dohme-llc","name":"V118C (Stage 1)","developer":"Merck Sharp & Dohme LLC","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-v118c-stage-1-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2028-10-24 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-05","decision":"2031-11","routine_use":"2031-11"},"typical":{"submission":"2034-11","decision":"2035-09","routine_use":"2035-12"},"slow":{"submission":"2040-05","decision":"2041-08","routine_use":"2042-04"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-05","decision":"2032-02","routine_use":"2032-03"},"typical":{"submission":"2034-11","decision":"2036-01","routine_use":"2036-07"},"slow":{"submission":"2040-05","decision":"2042-01","routine_use":"2043-07"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-05","decision":"2031-11","routine_use":"2031-12"},"typical":{"submission":"2034-11","decision":"2035-09","routine_use":"2036-01"},"slow":{"submission":"2040-05","decision":"2041-08","routine_use":"2042-08"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-h5-flu-investigational-medical-product-imp-1-sanofi","name":"H5 Flu IMP 2","developer":"Sanofi","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-h5-flu-investigational-medical-product-imp-1-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2027-04-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-11","decision":"2030-05","routine_use":"2030-05"},"typical":{"submission":"2033-05","decision":"2034-03","routine_use":"2034-06"},"slow":{"submission":"2038-11","decision":"2040-02","routine_use":"2040-10"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-11","decision":"2030-08","routine_use":"2030-09"},"typical":{"submission":"2033-05","decision":"2034-07","routine_use":"2035-01"},"slow":{"submission":"2038-11","decision":"2040-07","routine_use":"2042-01"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-11","decision":"2030-05","routine_use":"2030-06"},"typical":{"submission":"2033-05","decision":"2034-03","routine_use":"2034-07"},"slow":{"submission":"2038-11","decision":"2040-02","routine_use":"2041-02"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-adsorbed-acellular-pertussis-3-component-diphtheria-tetanus-pert","name":"DTcP-Hib-MCV4","developer":"CanSino Biologics Inc.","targetDisease":"Influenza","platform":"Conjugate vaccine","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-adsorbed-acellular-pertussis-3-component-diphtheria-tetanus-pert.html","expectedMilestone":"Primary completion (most advanced trial): 2029-02 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-09","decision":"2032-03","routine_use":"2032-03"},"typical":{"submission":"2035-03","decision":"2036-01","routine_use":"2036-04"},"slow":{"submission":"2040-09","decision":"2041-12","routine_use":"2042-08"}},"anchor":"2029-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-09","decision":"2032-06","routine_use":"2032-07"},"typical":{"submission":"2035-03","decision":"2036-05","routine_use":"2036-11"},"slow":{"submission":"2040-09","decision":"2042-05","routine_use":"2043-11"}},"anchor":"2029-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-09","decision":"2032-03","routine_use":"2032-04"},"typical":{"submission":"2035-03","decision":"2036-01","routine_use":"2036-05"},"slow":{"submission":"2040-09","decision":"2041-12","routine_use":"2042-12"}},"anchor":"2029-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-low-dose-rsv-mrna-vaccine-sinovac-biotech-co-ltd","name":"Low-dose RSV mRNA vaccine","developer":"Sinovac Biotech Co., Ltd","targetDisease":"RSV","platform":"mRNA","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-low-dose-rsv-mrna-vaccine-sinovac-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-06-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2026-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-high-dose-group-acyw135x-meningococcal-conjugate-vaccine-sinovac","name":"low-dose Group ACYW135X Meningococcal Conjugate Vaccine","developer":"Sinovac Life Sciences Co., Ltd.","targetDisease":"Meningococcal disease","platform":"Conjugate vaccine","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-high-dose-group-acyw135x-meningococcal-conjugate-vaccine-sinovac.html","expectedMilestone":"Primary completion (most advanced trial): 2026-09-10 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-recombinant-poliomyelitis-vaccine-rpv-serum-institute-of-india-p","name":"Recombinant Poliomyelitis Vaccine (rPV)","developer":"Serum Institute of India Pvt. Ltd.","targetDisease":"Polio","platform":"Protein / subunit","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"polio-vaccine.html","page":"/pipeline/ctgov-recombinant-poliomyelitis-vaccine-rpv-serum-institute-of-india-p.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2029-12"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-01"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-05"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2030-03","routine_use":"2030-04"},"typical":{"submission":"2032-12","decision":"2034-02","routine_use":"2034-08"},"slow":{"submission":"2038-06","decision":"2040-02","routine_use":"2041-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-02"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-09"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-lyophilized-haemophilus-influenzae-type-b-conjugate-vaccine-cans","name":"Haemophilus Influenzae Type b Conjugate Vaccine","developer":"CanSino Biologics Inc.","targetDisease":"Influenza","platform":"Conjugate vaccine","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-lyophilized-haemophilus-influenzae-type-b-conjugate-vaccine-cans.html","expectedMilestone":"Primary completion (most advanced trial): 2026-10 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-trivalent-rsv-hmpv-piv3-vaccine-candidate-sanofi","name":"bivalent (RSV/hMPV) unlicensed comparator","developer":"Sanofi","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-trivalent-rsv-hmpv-piv3-vaccine-candidate-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2026-04-21 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pg4-vaccine-in-buffer-1-with-low-dose-pa-001-pfizer","name":"PG4 in Buffer 1 with low dose PA-002","developer":"Pfizer","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pg4-vaccine-in-buffer-1-with-low-dose-pa-001-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2027-10-21 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-05","decision":"2030-11","routine_use":"2030-11"},"typical":{"submission":"2033-11","decision":"2034-09","routine_use":"2034-12"},"slow":{"submission":"2039-05","decision":"2040-08","routine_use":"2041-04"}},"anchor":"2027-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-05","decision":"2031-02","routine_use":"2031-03"},"typical":{"submission":"2033-11","decision":"2035-01","routine_use":"2035-07"},"slow":{"submission":"2039-05","decision":"2041-01","routine_use":"2042-07"}},"anchor":"2027-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-05","decision":"2030-11","routine_use":"2030-12"},"typical":{"submission":"2033-11","decision":"2034-09","routine_use":"2035-01"},"slow":{"submission":"2039-05","decision":"2040-08","routine_use":"2041-08"}},"anchor":"2027-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-vxb-241-60-mcg-low-dose-sanofi","name":"VXB-241 240 mcg","developer":"Sanofi","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-vxb-241-60-mcg-low-dose-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2025-02-14 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2025-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2025-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2025-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-covid-19-therapeutic-biologic-mix-novavax-covid-19-vaccine-plus-","name":"COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use","developer":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-covid-19-therapeutic-biologic-mix-novavax-covid-19-vaccine-plus-.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-18 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2029-12"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-01"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-05"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2030-03","routine_use":"2030-04"},"typical":{"submission":"2032-12","decision":"2034-02","routine_use":"2034-08"},"slow":{"submission":"2038-06","decision":"2040-02","routine_use":"2041-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-02"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-09"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-investigational-rsv-vaccine-1-glaxosmithkline","name":"Investigational RSV vaccine 1","developer":"GlaxoSmithKline","targetDisease":"RSV","platform":"mRNA","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-investigational-rsv-vaccine-1-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-04-13 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-20vpnc-pfizer","name":"20vPnC","developer":"Pfizer","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-20vpnc-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2027-05-14 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-12","decision":"2030-06","routine_use":"2030-06"},"typical":{"submission":"2033-06","decision":"2034-04","routine_use":"2034-07"},"slow":{"submission":"2038-12","decision":"2040-03","routine_use":"2040-11"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-12","decision":"2030-09","routine_use":"2030-10"},"typical":{"submission":"2033-06","decision":"2034-08","routine_use":"2035-02"},"slow":{"submission":"2038-12","decision":"2040-08","routine_use":"2042-02"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-12","decision":"2030-06","routine_use":"2030-07"},"typical":{"submission":"2033-06","decision":"2034-04","routine_use":"2034-08"},"slow":{"submission":"2038-12","decision":"2040-03","routine_use":"2041-03"}},"anchor":"2027-05","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-low-dose-strep-a-alum-glaxosmithkline","name":"Low dose Strep A Alum","developer":"GlaxoSmithKline","targetDisease":"Streptococcal Infections","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-low-dose-strep-a-alum-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2029-12"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-01"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-05"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2030-03","routine_use":"2030-04"},"typical":{"submission":"2032-12","decision":"2034-02","routine_use":"2034-08"},"slow":{"submission":"2038-06","decision":"2040-02","routine_use":"2041-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-02"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-09"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-v350a-merck-sharp-dohme-llc","name":"V350A","developer":"Merck Sharp & Dohme LLC","targetDisease":"Healthy","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-v350a-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2028-07-17 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-02","decision":"2031-08","routine_use":"2031-08"},"typical":{"submission":"2034-08","decision":"2035-06","routine_use":"2035-09"},"slow":{"submission":"2040-02","decision":"2041-05","routine_use":"2042-01"}},"anchor":"2028-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-02","decision":"2031-11","routine_use":"2031-12"},"typical":{"submission":"2034-08","decision":"2035-10","routine_use":"2036-04"},"slow":{"submission":"2040-02","decision":"2041-10","routine_use":"2043-04"}},"anchor":"2028-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-02","decision":"2031-08","routine_use":"2031-09"},"typical":{"submission":"2034-08","decision":"2035-06","routine_use":"2035-10"},"slow":{"submission":"2040-02","decision":"2041-05","routine_use":"2042-05"}},"anchor":"2028-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-placebo-vaxcyte-inc","name":"VAX-A1 Low","developer":"Vaxcyte, Inc.","targetDisease":"Group A Streptococcal Infection","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-placebo-vaxcyte-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-01","routine_use":"2031-01"},"typical":{"submission":"2034-01","decision":"2034-11","routine_use":"2035-02"},"slow":{"submission":"2039-07","decision":"2040-10","routine_use":"2041-06"}},"anchor":"2027-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-04","routine_use":"2031-05"},"typical":{"submission":"2034-01","decision":"2035-03","routine_use":"2035-09"},"slow":{"submission":"2039-07","decision":"2041-03","routine_use":"2042-09"}},"anchor":"2027-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-07","decision":"2031-01","routine_use":"2031-02"},"typical":{"submission":"2034-01","decision":"2034-11","routine_use":"2035-03"},"slow":{"submission":"2039-07","decision":"2040-10","routine_use":"2041-10"}},"anchor":"2027-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-durvalumab-astrazeneca","name":"Durvalumab","developer":"AstraZeneca","targetDisease":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-durvalumab-astrazeneca.html","expectedMilestone":"Primary completion (most advanced trial): 2027-06-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-01","decision":"2030-07","routine_use":"2030-07"},"typical":{"submission":"2033-07","decision":"2034-05","routine_use":"2034-08"},"slow":{"submission":"2039-01","decision":"2040-04","routine_use":"2040-12"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-01","decision":"2030-10","routine_use":"2030-11"},"typical":{"submission":"2033-07","decision":"2034-09","routine_use":"2035-03"},"slow":{"submission":"2039-01","decision":"2040-09","routine_use":"2042-03"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-01","decision":"2030-07","routine_use":"2030-08"},"typical":{"submission":"2033-07","decision":"2034-05","routine_use":"2034-09"},"slow":{"submission":"2039-01","decision":"2040-04","routine_use":"2041-04"}},"anchor":"2027-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-v118e-merck-sharp-dohme-llc","name":"V118E","developer":"Merck Sharp & Dohme LLC","targetDisease":"Healthy","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-v118e-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2027-11-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-06","decision":"2030-12","routine_use":"2030-12"},"typical":{"submission":"2033-12","decision":"2034-10","routine_use":"2035-01"},"slow":{"submission":"2039-06","decision":"2040-09","routine_use":"2041-05"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-06","decision":"2031-03","routine_use":"2031-04"},"typical":{"submission":"2033-12","decision":"2035-02","routine_use":"2035-08"},"slow":{"submission":"2039-06","decision":"2041-02","routine_use":"2042-08"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-06","decision":"2030-12","routine_use":"2031-01"},"typical":{"submission":"2033-12","decision":"2034-10","routine_use":"2035-02"},"slow":{"submission":"2039-06","decision":"2040-09","routine_use":"2041-09"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bnt116-biontech-se","name":"BNT116","developer":"BioNTech SE","targetDisease":"Non-Small Cell Lung Cancer","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-bnt116-biontech-se.html","expectedMilestone":"Primary completion (most advanced trial): 2030-02 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-09","decision":"2033-03","routine_use":"2033-03"},"typical":{"submission":"2036-03","decision":"2037-01","routine_use":"2037-04"},"slow":{"submission":"2041-09","decision":"2042-12","routine_use":"2043-08"}},"anchor":"2030-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-09","decision":"2033-06","routine_use":"2033-07"},"typical":{"submission":"2036-03","decision":"2037-05","routine_use":"2037-11"},"slow":{"submission":"2041-09","decision":"2043-05","routine_use":"2044-11"}},"anchor":"2030-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2032-09","decision":"2033-03","routine_use":"2033-04"},"typical":{"submission":"2036-03","decision":"2037-01","routine_use":"2037-05"},"slow":{"submission":"2041-09","decision":"2042-12","routine_use":"2043-12"}},"anchor":"2030-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pan-salmonella-with-alum-low-dose-vaccine-glaxosmithkline","name":"Typhoid Vi conjugate vaccine","developer":"GlaxoSmithKline","targetDisease":"Salmonella Infections","platform":"Conjugate vaccine","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-pan-salmonella-with-alum-low-dose-vaccine-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2027-11-14 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-06","decision":"2030-12","routine_use":"2030-12"},"typical":{"submission":"2033-12","decision":"2034-10","routine_use":"2035-01"},"slow":{"submission":"2039-06","decision":"2040-09","routine_use":"2041-05"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-06","decision":"2031-03","routine_use":"2031-04"},"typical":{"submission":"2033-12","decision":"2035-02","routine_use":"2035-08"},"slow":{"submission":"2039-06","decision":"2041-02","routine_use":"2042-08"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2030-06","decision":"2030-12","routine_use":"2031-01"},"typical":{"submission":"2033-12","decision":"2034-10","routine_use":"2035-02"},"slow":{"submission":"2039-06","decision":"2040-09","routine_use":"2041-09"}},"anchor":"2027-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-v540d-merck-sharp-dohme-llc","name":"V540D","developer":"Merck Sharp & Dohme LLC","targetDisease":"Healthy","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-v540d-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2029-12"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-01"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-05"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2030-03","routine_use":"2030-04"},"typical":{"submission":"2032-12","decision":"2034-02","routine_use":"2034-08"},"slow":{"submission":"2038-06","decision":"2040-02","routine_use":"2041-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-02"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-09"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bnt163-biontech-se","name":"BNT163","developer":"BioNTech SE","targetDisease":"Genital Herpes Simplex Type 2","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-bnt163-biontech-se.html","expectedMilestone":"Primary completion (most advanced trial): 2026-10 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mrna-1195-1-modernatx-inc","name":"mRNA-1195.1","developer":"ModernaTX, Inc.","targetDisease":"EBV","platform":"mRNA","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mrna-1195-1-modernatx-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2026-10-07 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-11"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2033-12"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-04"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2030-02","routine_use":"2030-03"},"typical":{"submission":"2032-11","decision":"2034-01","routine_use":"2034-07"},"slow":{"submission":"2038-05","decision":"2040-01","routine_use":"2041-07"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-05","decision":"2029-11","routine_use":"2029-12"},"typical":{"submission":"2032-11","decision":"2033-09","routine_use":"2034-01"},"slow":{"submission":"2038-05","decision":"2039-08","routine_use":"2040-08"}},"anchor":"2026-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-cldn6-car-t-biontech-cell-gene-therapies-gmbh","name":"CLDN6 CAR-T","developer":"BioNTech Cell & Gene Therapies GmbH","targetDisease":"Solid Tumor","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-cldn6-car-t-biontech-cell-gene-therapies-gmbh.html","expectedMilestone":"Primary completion (most advanced trial): 2028-08 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-03","decision":"2031-09","routine_use":"2031-09"},"typical":{"submission":"2034-09","decision":"2035-07","routine_use":"2035-10"},"slow":{"submission":"2040-03","decision":"2041-06","routine_use":"2042-02"}},"anchor":"2028-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-03","decision":"2031-12","routine_use":"2032-01"},"typical":{"submission":"2034-09","decision":"2035-11","routine_use":"2036-05"},"slow":{"submission":"2040-03","decision":"2041-11","routine_use":"2043-05"}},"anchor":"2028-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2031-03","decision":"2031-09","routine_use":"2031-10"},"typical":{"submission":"2034-09","decision":"2035-07","routine_use":"2035-11"},"slow":{"submission":"2040-03","decision":"2041-06","routine_use":"2042-06"}},"anchor":"2028-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-gardasil-9-g9-merck-sharp-dohme-llc","name":"V540B","developer":"Merck Sharp & Dohme LLC","targetDisease":"Healthy","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-gardasil-9-g9-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2026-11-20 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2029-12"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-01"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-05"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2030-03","routine_use":"2030-04"},"typical":{"submission":"2032-12","decision":"2034-02","routine_use":"2034-08"},"slow":{"submission":"2038-06","decision":"2040-02","routine_use":"2041-08"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-06","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2032-12","decision":"2033-10","routine_use":"2034-02"},"slow":{"submission":"2038-06","decision":"2039-09","routine_use":"2040-09"}},"anchor":"2026-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-fluzone-hd-influenza-vaccine-cidara-therapeutics-inc-a-subsidiar","name":"Fluzone HD influenza vaccine","developer":"Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","targetDisease":"Healthy Participants","platform":"Biological (unspecified platform)","stage":"phase_1","stage_label":"Phase 1","stage_at_discontinuation":null,"progress_percent":15,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-fluzone-hd-influenza-vaccine-cidara-therapeutics-inc-a-subsidiar.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-01"},"typical":{"submission":"2033-01","decision":"2033-11","routine_use":"2034-02"},"slow":{"submission":"2038-07","decision":"2039-10","routine_use":"2040-06"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-04","routine_use":"2030-05"},"typical":{"submission":"2033-01","decision":"2034-03","routine_use":"2034-09"},"slow":{"submission":"2038-07","decision":"2040-03","routine_use":"2041-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2033-01","decision":"2033-11","routine_use":"2034-03"},"slow":{"submission":"2038-07","decision":"2039-10","routine_use":"2040-10"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-mva-smallpox-vaccine-sanofi-pasteur-a-sanofi-company","name":"MVA Smallpox Vaccine","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"HIV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-mva-smallpox-vaccine-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2007-07 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-v590-merck-sharp-dohme-llc","name":"V590","developer":"Merck Sharp & Dohme LLC","targetDisease":"COVID-19","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"covid-vaccine.html","page":"/pipeline/ctgov-v590-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2021-02-18 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-comparator-rotateq-merck-sharp-dohme-llc","name":"Comparator: RotaTeq","developer":"Merck Sharp & Dohme LLC","targetDisease":"Rotavirus","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rotavirus-vaccine.html","page":"/pipeline/ctgov-comparator-rotateq-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2010-01 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gsk2231395a-glaxosmithkline","name":"GSK2231395A","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-gsk2231395a-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2009-04-07 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-investigational-h7n9-vaccine-gsk3277510a-glaxosmithkline","name":"Investigational H7N9 vaccine GSK3277510A","developer":"GlaxoSmithKline","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-investigational-h7n9-vaccine-gsk3277510a-glaxosmithkline.html","expectedMilestone":"Primary completion (most advanced trial): 2016-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-ixiaro-valneva-austria-gmbh","name":"IXIARO","developer":"Valneva Austria GmbH","targetDisease":"Japanese encephalitis","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"japanese-encephalitis-vaccine.html","page":"/pipeline/ctgov-ixiaro-valneva-austria-gmbh.html","expectedMilestone":"Primary completion (most advanced trial): 2012-12 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-mva-bn-rsv-bavarian-nordic","name":"MVA-BN-RSV","developer":"Bavarian Nordic","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-mva-bn-rsv-bavarian-nordic.html","expectedMilestone":"Primary completion (most advanced trial): 2017-10-27 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-cv9202-curevac","name":"CV9202","developer":"CureVac","targetDisease":"Non-Small Cell Lung Carcinoma","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-cv9202-curevac.html","expectedMilestone":"Primary completion (most advanced trial): 2016-07 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-v941-merck-sharp-dohme-llc","name":"V941","developer":"Merck Sharp & Dohme LLC","targetDisease":"Neoplasms","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-v941-merck-sharp-dohme-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2022-08-25 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-neo-pv-01-biontech-us-inc","name":"APX005M","developer":"BioNTech US Inc.","targetDisease":"Metastatic Melanoma","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-neo-pv-01-biontech-us-inc.html","expectedMilestone":"Primary completion (most advanced trial): 2020-05-05 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-ad4-mgag-emergent-biosolutions","name":"Ad4-mgag","developer":"Emergent BioSolutions","targetDisease":"HIV","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-ad4-mgag-emergent-biosolutions.html","expectedMilestone":"Primary completion (most advanced trial): 2017-02 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-jnj-64041757-cohort-1a-and-1b-janssen-research-development-llc","name":"JNJ-64041757 (Cohort 1A and 1B)","developer":"Janssen Research & Development, LLC","targetDisease":"Carcinoma, Non-Small-Cell Lung","platform":"Live attenuated","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-jnj-64041757-cohort-1a-and-1b-janssen-research-development-llc.html","expectedMilestone":"Primary completion (most advanced trial): 2018-08-14 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-hiv-1-gag-dna-formulated-with-bupivacaine-wyeth-is-now-a-wholly-","name":"IL-15 DNA (formulated with bupivacaine)","developer":"Wyeth is now a wholly owned subsidiary of Pfizer","targetDisease":"HIV","platform":"DNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-hiv-1-gag-dna-formulated-with-bupivacaine-wyeth-is-now-a-wholly-.html","expectedMilestone":"See linked ClinicalTrials.gov records for primary completion dates","jurisdictions":{}},{"candidateId":"ctgov-vaccine-diluent-buffer-sanofi","name":"Vaccine diluent buffer","developer":"Sanofi","targetDisease":"Clostridium Difficile Infection","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-vaccine-diluent-buffer-sanofi.html","expectedMilestone":"Primary completion (most advanced trial): 2006-06 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-hsv-2-formulation-1-sanofi-pasteur-a-sanofi-company","name":"HSV 2 Formulation 1","developer":"Sanofi Pasteur, a Sanofi Company","targetDisease":"Genital Herpes","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-hsv-2-formulation-1-sanofi-pasteur-a-sanofi-company.html","expectedMilestone":"Primary completion (most advanced trial): 2021-05-19 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-pf-06755992-pfizer","name":"PF-06755992","developer":"Pfizer","targetDisease":"Prostatic Neoplasms","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-pf-06755992-pfizer.html","expectedMilestone":"Primary completion (most advanced trial): 2021-02-23 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-pxvx0047-vaccine-emergent-biosolutions","name":"PXVX0047 Vaccine","developer":"Emergent BioSolutions","targetDisease":"Adenoviral Infection","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-pxvx0047-vaccine-emergent-biosolutions.html","expectedMilestone":"Primary completion (most advanced trial): 2017-11-27 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-lower-dose-formulation-of-hsv-vaccine-gsk4108771a-glaxosmithklin","name":"Lower dose formulation of HSV vaccine (GSK4108771A)","developer":"GlaxoSmithKline","targetDisease":"Herpes Simplex","platform":"Biological (unspecified platform)","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-lower-dose-formulation-of-hsv-vaccine-gsk4108771a-glaxosmithklin.html","expectedMilestone":"Primary completion (most advanced trial): 2021-05-26 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-cv09070101-mrna-vaccine-cvhnlc-50-g-curevac","name":"CV09070101 mRNA vaccine (CVHNLC) 50 µg","developer":"CureVac","targetDisease":"Squamous NSCLC","platform":"mRNA","stage":"discontinued","stage_label":"Discontinued","stage_at_discontinuation":"phase_1","progress_percent":15,"grade":"none","grade_reason":"Discontinued or withdrawn; tracked, not projected.","lastVerified":"2026-07-10","relatedVaccinePage":null,"page":"/pipeline/ctgov-cv09070101-mrna-vaccine-cvhnlc-50-g-curevac.html","expectedMilestone":"Primary completion (most advanced trial): 2029-12-31 (registry estimate)","jurisdictions":{}},{"candidateId":"ctgov-gardasil-9-emory-university","name":"Gardasil-9","developer":"Emory University","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-gardasil-9-emory-university.html","expectedMilestone":"Primary completion (most advanced trial): 2028-09 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2024-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2024-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2024-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-influenza-vaccination-wroclaw-medical-university","name":"Influenza vaccination","developer":"Wroclaw Medical University","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-influenza-vaccination-wroclaw-medical-university.html","expectedMilestone":"Primary completion (most advanced trial): 2025-11-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-11","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-bcg-vaccine-bandim-health-project","name":"BCG vaccine","developer":"Bandim Health Project","targetDisease":"Measles / Mumps / Rubella","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"mmr-vaccine.html","page":"/pipeline/ctgov-bcg-vaccine-bandim-health-project.html","expectedMilestone":"Primary completion (most advanced trial): 2025-12-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-hpv-vaccine-university-of-washington","name":"HPV vaccine","developer":"University of Washington","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-hpv-vaccine-university-of-washington.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-diphtheria-toxoid-tetanus-toxoid-acellular-pertussis-vaccine-ads","name":"Recombinant Human Papillomavirus Bivalent Vaccine","developer":"National Cancer Institute (NCI)","targetDisease":"HPV","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-diphtheria-toxoid-tetanus-toxoid-acellular-pertussis-vaccine-ads.html","expectedMilestone":"Primary completion (most advanced trial): 2025-08-21 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pneumococcal-vaccine-university-of-sao-paulo-general-hospital","name":"Pneumococcal Vaccine","developer":"University of Sao Paulo General Hospital","targetDisease":"Autoimmune Rheumatologic Disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pneumococcal-vaccine-university-of-sao-paulo-general-hospital.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pertagen-vaccine-mahidol-university","name":"Adacel® vaccine","developer":"Mahidol University","targetDisease":"Diphtheria / Tetanus / Pertussis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"dtap-vaccine.html","page":"/pipeline/ctgov-pertagen-vaccine-mahidol-university.html","expectedMilestone":"Primary completion (most advanced trial): 2026-03 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-03","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-hpv-nonavalent-vaccine-gardasil-9-canadian-immunization-research","name":"HPV nonavalent vaccine (Gardasil-9)","developer":"Canadian Immunization Research Network","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-hpv-nonavalent-vaccine-gardasil-9-canadian-immunization-research.html","expectedMilestone":"Primary completion (most advanced trial): 2026-02 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-recombinant-herpes-zoster-vaccine-shingrix-tor-biering-s-rensen","name":"Recombinant Herpes Zoster Vaccine (Shingrix)","developer":"Tor Biering-Sørensen","targetDisease":"Varicella / Zoster","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-recombinant-herpes-zoster-vaccine-shingrix-tor-biering-s-rensen.html","expectedMilestone":"Primary completion (most advanced trial): 2029-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-01"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-02"},"slow":{"submission":"2030-10","decision":"2032-01","routine_use":"2032-09"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-04","routine_use":"2030-05"},"typical":{"submission":"2030-01","decision":"2031-03","routine_use":"2031-09"},"slow":{"submission":"2030-10","decision":"2032-06","routine_use":"2033-12"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-07","decision":"2030-01","routine_use":"2030-02"},"typical":{"submission":"2030-01","decision":"2030-11","routine_use":"2031-03"},"slow":{"submission":"2030-10","decision":"2032-01","routine_use":"2033-01"}},"anchor":"2029-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-human-papillomavirus-9-valent-vaccine-recombinant-louisiana-stat","name":"human papillomavirus vaccine, recombinant","developer":"Louisiana State University Health Sciences Center in New Orleans","targetDisease":"HPV","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-human-papillomavirus-9-valent-vaccine-recombinant-louisiana-stat.html","expectedMilestone":"Primary completion (most advanced trial): 2025-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-prevenar-13-pneumovax-23-poitiers-university-hospital","name":"PREVENAR20","developer":"Poitiers University Hospital","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-prevenar-13-pneumovax-23-poitiers-university-hospital.html","expectedMilestone":"Primary completion (most advanced trial): 2028-06 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-03","routine_use":"2029-03"},"typical":{"submission":"2029-03","decision":"2030-01","routine_use":"2030-04"},"slow":{"submission":"2029-12","decision":"2031-03","routine_use":"2031-11"}},"anchor":"2028-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-06","routine_use":"2029-07"},"typical":{"submission":"2029-03","decision":"2030-05","routine_use":"2030-11"},"slow":{"submission":"2029-12","decision":"2031-08","routine_use":"2033-02"}},"anchor":"2028-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2028-09","decision":"2029-03","routine_use":"2029-04"},"typical":{"submission":"2029-03","decision":"2030-01","routine_use":"2030-05"},"slow":{"submission":"2029-12","decision":"2031-03","routine_use":"2032-03"}},"anchor":"2028-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-nonavalent-hpv-vaccine-9vhpv-gardasil-9-miquel-angel-pavon-ribas","name":"Nonavalent HPV vaccine (9vHPV/Gardasil-9™).","developer":"Miquel Angel Pavon Ribas","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-nonavalent-hpv-vaccine-9vhpv-gardasil-9-miquel-angel-pavon-ribas.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-measles-mumps-rubella-vaccine-mmr-laure-pittet-md-phd","name":"Measles-Mumps-Rubella vaccine (MMR)","developer":"Laure Pittet, MD-PhD","targetDisease":"Measles / Mumps / Rubella","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"mmr-vaccine.html","page":"/pipeline/ctgov-measles-mumps-rubella-vaccine-mmr-laure-pittet-md-phd.html","expectedMilestone":"Primary completion (most advanced trial): 2026-04 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-laiv-nasal-vaccine-is-chosen-as-a-model-viral-infection-universi","name":"LAIV nasal vaccine is chosen as a model viral infection","developer":"University of North Carolina, Chapel Hill","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-laiv-nasal-vaccine-is-chosen-as-a-model-viral-infection-universi.html","expectedMilestone":"Primary completion (most advanced trial): 2028-12-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-09"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-10"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-05"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2029-09","decision":"2030-11","routine_use":"2031-05"},"slow":{"submission":"2030-06","decision":"2032-02","routine_use":"2033-08"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-10"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-11"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-09"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-9-valent-hpv-vaccine-cecolin-9-xiamen-innovax-biotech-co-ltd","name":"9-valent HPV vaccine (Cecolin 9)","developer":"Xiamen Innovax Biotech Co., Ltd","targetDisease":"HPV","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-9-valent-hpv-vaccine-cecolin-9-xiamen-innovax-biotech-co-ltd.html","expectedMilestone":"Primary completion (most advanced trial): 2027-02-28 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-05","decision":"2027-11","routine_use":"2027-11"},"typical":{"submission":"2027-11","decision":"2028-09","routine_use":"2028-12"},"slow":{"submission":"2028-08","decision":"2029-11","routine_use":"2030-07"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-05","decision":"2028-02","routine_use":"2028-03"},"typical":{"submission":"2027-11","decision":"2029-01","routine_use":"2029-07"},"slow":{"submission":"2028-08","decision":"2030-04","routine_use":"2031-10"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-05","decision":"2027-11","routine_use":"2027-12"},"typical":{"submission":"2027-11","decision":"2028-09","routine_use":"2029-01"},"slow":{"submission":"2028-08","decision":"2029-11","routine_use":"2030-11"}},"anchor":"2027-02","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-nonavalent-hpv-vaccine-university-of-british-columbia","name":"Nonavalent HPV vaccine","developer":"University of British Columbia","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-nonavalent-hpv-vaccine-university-of-british-columbia.html","expectedMilestone":"Primary completion (most advanced trial): 2026-08 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-serogroup-b-meningococal-vaccine-university-ghent","name":"Serogroup B meningococal vaccine","developer":"University Ghent","targetDisease":"Meningococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-serogroup-b-meningococal-vaccine-university-ghent.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-trumenba-emory-university","name":"Trumenba","developer":"Emory University","targetDisease":"Meningococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"meningococcal-vaccine.html","page":"/pipeline/ctgov-trumenba-emory-university.html","expectedMilestone":"Primary completion (most advanced trial): 2026-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-09"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-10"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-05"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-12","routine_use":"2028-01"},"typical":{"submission":"2027-09","decision":"2028-11","routine_use":"2029-05"},"slow":{"submission":"2028-06","decision":"2030-02","routine_use":"2031-08"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-03","decision":"2027-09","routine_use":"2027-10"},"typical":{"submission":"2027-09","decision":"2028-07","routine_use":"2028-11"},"slow":{"submission":"2028-06","decision":"2029-09","routine_use":"2030-09"}},"anchor":"2026-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-early-intervention-centre-hospitalier-universitaire-de-saint-eti","name":"Early intervention","developer":"Centre Hospitalier Universitaire de Saint Etienne","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-early-intervention-centre-hospitalier-universitaire-de-saint-eti.html","expectedMilestone":"Primary completion (most advanced trial): 2028-10-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-01","decision":"2029-07","routine_use":"2029-07"},"typical":{"submission":"2029-07","decision":"2030-05","routine_use":"2030-08"},"slow":{"submission":"2030-04","decision":"2031-07","routine_use":"2032-03"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-01","decision":"2029-10","routine_use":"2029-11"},"typical":{"submission":"2029-07","decision":"2030-09","routine_use":"2031-03"},"slow":{"submission":"2030-04","decision":"2031-12","routine_use":"2033-06"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-01","decision":"2029-07","routine_use":"2029-08"},"typical":{"submission":"2029-07","decision":"2030-05","routine_use":"2030-09"},"slow":{"submission":"2030-04","decision":"2031-07","routine_use":"2032-07"}},"anchor":"2028-10","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-heplisav-b-injectable-product-2-dose-regimen-mercy-medical-cente","name":"Heplisav-B Injectable Product, 2-dose regimen","developer":"Mercy Medical Center","targetDisease":"Hepatitis B","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hepatitis-b-vaccine.html","page":"/pipeline/ctgov-heplisav-b-injectable-product-2-dose-regimen-mercy-medical-cente.html","expectedMilestone":"Primary completion (most advanced trial): 2028-12-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-09"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-10"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-05"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-12","routine_use":"2030-01"},"typical":{"submission":"2029-09","decision":"2030-11","routine_use":"2031-05"},"slow":{"submission":"2030-06","decision":"2032-02","routine_use":"2033-08"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2029-03","decision":"2029-09","routine_use":"2029-10"},"typical":{"submission":"2029-09","decision":"2030-07","routine_use":"2030-11"},"slow":{"submission":"2030-06","decision":"2031-09","routine_use":"2032-09"}},"anchor":"2028-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-vaccine-administration-women-and-infants-hospital-of-rhode-islan","name":"Vaccine administration","developer":"Women and Infants Hospital of Rhode Island","targetDisease":"Diphtheria / Tetanus / Pertussis","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"dtap-vaccine.html","page":"/pipeline/ctgov-vaccine-administration-women-and-infants-hospital-of-rhode-islan.html","expectedMilestone":"Primary completion (most advanced trial): 2025-06-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-06","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-06","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-06","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-pcv15-university-of-oxford","name":"PCV15","developer":"University of Oxford","targetDisease":"Pneumococcal disease","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"pcv-vaccine.html","page":"/pipeline/ctgov-pcv15-university-of-oxford.html","expectedMilestone":"Primary completion (most advanced trial): 2025-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-tdap-vaccine-administration-canadian-immunization-research-netwo","name":"RSV Vaccine","developer":"Canadian Immunization Research Network","targetDisease":"RSV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"rsv-vaccine.html","page":"/pipeline/ctgov-tdap-vaccine-administration-canadian-immunization-research-netwo.html","expectedMilestone":"Primary completion (most advanced trial): 2026-07 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-flumist-washington-university-school-of-medicine","name":"FluMist","developer":"Washington University School of Medicine","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-flumist-washington-university-school-of-medicine.html","expectedMilestone":"Primary completion (most advanced trial): 2026-09 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-09","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-recombinant-zoster-vaccine-rzv-university-of-sao-paulo-general-h","name":"Recombinant Zoster Vaccine (RZV)","developer":"University of Sao Paulo General Hospital","targetDisease":"Varicella / Zoster","platform":"Protein / subunit","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"varicella-vaccine.html","page":"/pipeline/ctgov-recombinant-zoster-vaccine-rzv-university-of-sao-paulo-general-h.html","expectedMilestone":"Primary completion (most advanced trial): 2027-07-30 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-10","decision":"2028-04","routine_use":"2028-04"},"typical":{"submission":"2028-04","decision":"2029-02","routine_use":"2029-05"},"slow":{"submission":"2029-01","decision":"2030-04","routine_use":"2030-12"}},"anchor":"2027-07","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-10","decision":"2028-07","routine_use":"2028-08"},"typical":{"submission":"2028-04","decision":"2029-06","routine_use":"2029-12"},"slow":{"submission":"2029-01","decision":"2030-09","routine_use":"2032-03"}},"anchor":"2027-07","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-10","decision":"2028-04","routine_use":"2028-05"},"typical":{"submission":"2028-04","decision":"2029-02","routine_use":"2029-06"},"slow":{"submission":"2029-01","decision":"2030-04","routine_use":"2031-04"}},"anchor":"2027-07","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-yellow-fever-vaccination-17-dd-biomanguinhos-oswaldo-cruz-founda","name":"Yellow Fever vaccination (17 DD Biomanguinhos)","developer":"Oswaldo Cruz Foundation","targetDisease":"Yellow fever","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"yellow-fever-vaccine.html","page":"/pipeline/ctgov-yellow-fever-vaccination-17-dd-biomanguinhos-oswaldo-cruz-founda.html","expectedMilestone":"Primary completion (most advanced trial): 2018-12 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2018-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2018-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2018-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-9-valent-hpv-vaccine-2-doses-alternate-timing-the-university-of-","name":"9-valent HPV vaccine, 3 doses standard timing","developer":"The University of Texas Medical Branch, Galveston","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-9-valent-hpv-vaccine-2-doses-alternate-timing-the-university-of-.html","expectedMilestone":"Primary completion (most advanced trial): 2026-08 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2026-08","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-seasonal-influenza-vaccine-university-of-pennsylvania","name":"Seasonal influenza vaccine","developer":"University of Pennsylvania","targetDisease":"Influenza","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"influenza-vaccine.html","page":"/pipeline/ctgov-seasonal-influenza-vaccine-university-of-pennsylvania.html","expectedMilestone":"Primary completion (most advanced trial): 2027-04-01 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-07","decision":"2028-01","routine_use":"2028-01"},"typical":{"submission":"2028-01","decision":"2028-11","routine_use":"2029-02"},"slow":{"submission":"2028-10","decision":"2030-01","routine_use":"2030-09"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-07","decision":"2028-04","routine_use":"2028-05"},"typical":{"submission":"2028-01","decision":"2029-03","routine_use":"2029-09"},"slow":{"submission":"2028-10","decision":"2030-06","routine_use":"2031-12"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-07","decision":"2028-01","routine_use":"2028-02"},"typical":{"submission":"2028-01","decision":"2028-11","routine_use":"2029-03"},"slow":{"submission":"2028-10","decision":"2030-01","routine_use":"2031-01"}},"anchor":"2027-04","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}},{"candidateId":"ctgov-gardasil9-miriam-elfstr-m","name":"Gardasil9","developer":"Miriam Elfström","targetDisease":"HPV","platform":"Biological (unspecified platform)","stage":"phase_3","stage_label":"Phase 3","stage_at_discontinuation":null,"progress_percent":60,"grade":"C","grade_reason":"Stage known from the trial registry only; no jurisdiction-specific filing date.","lastVerified":"2026-07-10","relatedVaccinePage":"hpv-vaccine.html","page":"/pipeline/ctgov-gardasil9-miriam-elfstr-m.html","expectedMilestone":"Primary completion (most advanced trial): 2025-12-31 (registry estimate)","jurisdictions":{"US":{"regulator":"FDA (CBER)","recommender":"ACIP (CDC)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-07"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-08"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-03"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"EU":{"regulator":"EMA (CHMP) and European Commission","recommender":"national bodies (STIKO, HAS, Folkhälsomyndigheten and others)","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-10","routine_use":"2027-11"},"typical":{"submission":"2027-07","decision":"2028-09","routine_use":"2029-03"},"slow":{"submission":"2028-04","decision":"2029-12","routine_use":"2031-06"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"Canada":{"regulator":"Health Canada","recommender":"NACI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"windows":{"fast":{"submission":"2027-01","decision":"2027-07","routine_use":"2027-08"},"typical":{"submission":"2027-07","decision":"2028-05","routine_use":"2028-09"},"slow":{"submission":"2028-04","decision":"2029-07","routine_use":"2030-07"}},"anchor":"2025-12","anchor_type":"company or registry readout date"},"UK":{"regulator":"MHRA","recommender":"JCVI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used."},"Australia":{"regulator":"TGA","recommender":"ATAGI","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"TGA registration-timeframe pages timed out on 2026-10-24; no target is used."},"Japan":{"regulator":"PMDA / MHLW","recommender":"MHLW immunisation subcommittee","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure."},"WHO":{"regulator":"WHO Prequalification","recommender":"SAGE","status":"no jurisdiction-specific filing known","status_date":null,"date_type":null,"note":"WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used."}}}]}